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ABSTRACT OF DISSERTATION

GENETIC MOUSE MODELS OF LIVER DISEASE:
POTENTIAL ROLES OF ZHX2 (AFR1) AND AFR2
IN DAMAGE AND REGENERATION
The liver is the largest internal organ in mammals and responsible for carrying out
various processes, including lipid and carbohydrate metabolism, detoxification of
chemicals, and production of serum proteins. Liver damage, which can be caused by a
variety of agents including viral infection, environmental toxins, alcohol and excessive
dietary fats, can cause dysregulation of these critical functions, leading to worsening liver
pathophysiology and impacting health. However, the liver has the remarkable ability to
regenerate when damaged. Hepatocytes, which comprise a majority of liver cells, are
relatively quiescent under healthy conditions. Upon injury, remaining hepatocytes can
proliferate to recover from liver damage while performing their metabolic functions.
Unfortunately, persistent injury can progressively lead to hepatitis, fibrosis, and
ultimately end-stage liver disease, cirrhosis, and liver cancer. Overall, liver disease is the
fifth leading cause of death worldwide and a growing healthcare problem in the United
States and other western countries. A better understanding of liver regeneration could be
used clinically to treat a wide range of liver diseases.
Studies in different mouse strains have provided genetic models to understand
aspects of liver gene regulation and liver disease. Two regulators of the liver-derived
serum protein alpha-fetoprotein (AFP), alpha-fetoprotein regulator 1 and 2 (Afr1 and
Afr2), have been implicated to play a role in liver disease and regeneration. AFP is
normally expressed in the fetal liver, silenced at birth, and reactivated in liver
regeneration and liver cancer. Based on the unusually high AFP expression in adult
BALB/cJ mice, our lab identified Zinc Fingers and Homeoboxes 2 (Zhx2) as the gene
responsible for the Afr1 trait. BALB/cJ mice contain a natural mutation in the Zhx2 gene.
Additional studies have shown that Zhx2 is involved in several liver diseases, including
diet-induced fatty liver disease and hepatocellular carcinoma. In addition to these traits,
BALB/cJ mice have been shown to have increased liver fibrosis after chronic treatment
with the hepatotoxin carbon tetrachloride (CCl4). The locus responsible for this trait,
called Hepatic fibrosis 1 (Hfib1), was mapped to the same region of Chromosome 15
(Chr15) as Zhx2, but the Hfib1 gene has not been identified.
During liver regeneration after acute treatment with CCl4, it was found that liver
AFP mRNA levels were much higher in C3H/HeJ mice than in C57BL/6J mice. The
locus that controls this strain-specific difference in AFP reactivation was called Afr2;
C3H/HeJ and C57BL/6 mice are thought to contain the Afr2a and Afr2b alleles,
respectively. The Afr2 locus has been mapped to Chr2, but the Afr2 gene has not been
identified.
This dissertation tested the hypothesis that Zhx2 is responsible for the Hfib1 trait
in BALB/cJ mice. Using BALB/cJ mice and C57BL/6J mice with a targeted mutation in
the Zhx2 gene, my data indicates that Zhx2 is not responsible for the Hfib1 trait. Mice
with low Zhx2 expression did not have more significant inflammation, liver damage, or

fibrosis than mice with wild-type Zhx2 levels. These data suggest that another gene,
presumably within the same region as Zhx2, is responsible for the Hfib1 phenotype in
BALB/cJ mice. I also analyzed the Afr2 trait across several different strains of mice. My
studies indicate that the strains 129X1/SvJ, C3H/HeJ, and DBA/2J contain the Afr2a
allele, whereas mice in the C57 lineage (C57BL/6J, C57BL/6N, C57BL/10) contain the
Afr2b allele. I also demonstrate that F1 offspring of 129X1/SvJ mice and C57BL/6J mice
display an intermediate AFP reactivation phenotype, suggesting that the Afr2a and Afr2b
alleles are co-dominant. These data provide the framework for future studies to identify
the Afr2 gene. Taken together, my results indicate that regulators of gene expression
within the liver, as defined by differences within mouse strains, can provide insight into
liver disease and regeneration.
KEYWORDS: Zinc Fingers and Homeoboxes 2, Alpha-fetoprotein, Afr2, Liver disease,
Liver regeneration, Gene regulation
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CHAPTER 1. INTRODUCTION
1.1 The Liver
The liver is the largest internal organ in mammals and carries out numerous
functions, including multiple metabolic processes such as glucose metabolism and lipid
homeostasis. The liver is a primary location for converting glucose into glycogen for
energy storage, enabling it to be utilized later [1], and is the setting for glycolysis, the
process of breaking down glucose to generate ATP for energy [2]. The liver is also
responsible for producing the key enzymes responsible for gluconeogenesis, including
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase, and fructose 1,6biphosphate [3]. The liver is also the site for producing serum proteins, including
numerous transport proteins such as albumin and alpha-fetoprotein (AFP) [4, 5].
The liver also is essential for both lipid production and breakdown. Hepatocytes
within the liver can generate lipid from excess glucose by converting the pyruvate
produced during glycolysis into acetyl-CoA. The process of de novo lipogenesis (DNL)
can use this acetyl-CoA to create fatty acids [3, 6, 7]. β-oxidation within the hepatocytes
can break down lipids for energy. β-oxidation reduces the lipid chain to make acetyl-CoA
within the mitochondria or peroxisomes, which can then be used for ATP production [3,
6, 7].
The liver has an essential role in the metabolism and detoxification of numerous
endogenous and exogenous compounds. Many enzymes within the liver are responsible
for this process, categorized as Phase I, II, and III metabolizing enzymes. Phase I
enzymes include those that have a primary role in oxidizing xenobiotics for subsequent
breakdown [8, 9]. Cytochrome P450s (Cyp) are a family of proteins that are classified in
1

this group and are responsible for approximately 75-95% of the breakdown of the
compounds that enter the liver from the bloodstream [10, 11]. Although this process has a
vital role in eliminating toxic compounds, some of the metabolites from these reactions
are more toxic than the original compounds [12, 13]. For example, environmental
chemicals such as carbon tetrachloride (CCl4) can be converted by Cyp2E1 into highly
reactive radical products trichloromethyl (CCl3ꞏ) and trichloromethyl peroxyl (CCl3OOꞏ),
both of which can cause oxidative damage to cellular components [12, 14]. Cyps can
metabolize compounds into carcinogens, like Diethylnitrosamine (DEN), which can
cause initiate tumorigenesis in the liver [15]. This occurs after Cyp2E1 metabolizes DEN
into the metabolite methyldiazohydroxide, which can create methylated guanine, creating
DNA adducts [13]. In addition, Phase II metabolizing enzymes function as transferases
and include the enzymes glutathione-s-transferases (GST), UDP-glucuronosyltransferases
(UGT), sulfotransferases (SULT), among others [16]. Phase II enzymes can metabolize
processes such as removing free radicals, conjugating to compounds to help with
excretion, and metabolizing certain endogenous and exogenous compounds [9]. Phase III
metabolizing enzymes serve as transporters for small and large compounds, including the
transporters multidrug resistance-associated protein (MRP), P-glycoprotein (P-gp), and
organic anion transporter (OAT) [17]. These transporters are important for shuttling
nutrients and metabolites to targeted areas [18].
1.2 Liver Structure and Zonality
Liver functions depend on the overall liver structure and the various cell types
that comprise this organ. Hepatocytes, which comprise roughly 80% of total liver volume
and ~60% of liver cells, carry out a majority of liver functions, including carbohydrate,
2

lipid, and drug metabolism processes [2, 19]. The resident macrophages, called Kupffer
cells, make up the largest population of macrophages in the body. Kupffer cells are
essential for innate immune responses both locally and throughout the body [20, 21]. In
addition to the Kupffer cells, other immune cells include NK, neutrophils, and dendritic
cells that are important for responding to liver injury [22]. The hepatic stellate cells are
generally quiescent pericytes that serve as the body’s primary location for Vitamin A
storage. However, persistent liver damage results in the activation of stellate cells into
myofibroblasts, which produce several extracellular matrix proteins that contribute to
liver fibrosis [23]. Liver sinusoidal endothelial cells line the blood vessels, playing an
important role in regulating blood flow [24]. Cholangiocytes line the bile ducts and are
critical for delivering bile acids from the liver to the GI tract [25].
The liver architecture is organized into repeating hexagonal units called lobules.
At the middle of each lobule is the central vein, whereas each axis of the hexagon
consists of a portal triad, which is comprised of a portal vein, hepatic artery, and bile duct
[26] (Figure 1.1 A). On average, the distance between the central veins and portal triads
spans roughly 15 hepatocytes. Blood enters the liver through the portal vein and hepatic
artery rich in nutrients from the GI tract and oxygen from the heart, respectively. The
blood then travels through a sinusoidal space between plates of hepatocytes lined by a
layer of endothelial cells. During this time, the exchange of materials between the
bloodstream and hepatocytes occurs [27] (Figure 1.1 B).
Many functions within the liver are managed, in large part, by a phenomenon
called metabolic zonation. Hepatocytes within the liver carry out distinct functions based
on their location within the liver lobule. The region surrounding the portal triad, called
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zone 1 or the periportal region, contains hepatocytes that perform oxygen-dependent
processes such as lipolysis, glucogenesis, and cholesterol synthesis [28, 29]. The region
surrounding the central vein, called zone 3 or pericentral region, contains hepatocytes that
carry out glycolysis and lipogenesis [28, 30] (Figure 1.1 C). Thus, the expression of
subsets of hepatic genes is based on their location within the lobule [31]. Pericentrally
expressed genes are involved in glycolysis (glyceraldehyde-3-phosphate dehydrogenase,
glucose-6-phosphate isomerase), glutamine synthesis (glutamine synthetase), and drug
metabolism (Cyp2e1) [30, 32]. In addition, periportal hepatocytes express genes crucial
for gluconeogenesis (phosphoenolpyruvate carboxykinase, tyrosine aminotransferase),
fatty acid oxidation (acetyl-CoA carboxylase), and bile acid formation (carnitine
palmitoyltransferase 1) [29, 33-35]. Genes expressed in zone 2, which is intermediate
between zones 1 and 3, are not known to have roles in specific metabolic processes but
have recently been speculated to play a role in liver homeostasis [36]. Although some
genes display strict or gradient zonal expression, some genes are not zonally expressed
[28, 34]. A significant contributor to liver zonation is Wnt/β-catenin signaling. Active catenin protein is normally only found in pericentral hepatocytes; this restricted
expression is due to certain Wnt proteins that are synthesized by endothelial cells
surrounding the central veins. When the β-catenin gene is deleted in hepatocytes,
pericentral genes are no longer expressed and liver regeneration is diminished [32]. In
contrast, deletion of the Adenomatous Polyposis Coli (APC) gene, which is part of a
complex that phosphorylates β-catenin in the periportal hepatocytes, leading to its
degradation, results in expression on pericentral genes in all hepatocytes [33]. In a 2019
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single-cell transcriptomics paper, reductions in zonal expression were found to be due to
reductions in Wnt secretion and signaling [28].
1.3 Liver Injury and Disease
The adult liver is usually a quiescent organ under healthy conditions with very
low cell turnover. However, hepatocytes can be damaged or killed by various agents,
leading to liver disease. These agents include viral infection [primarily Hepatitis B Virus
(HBV) and HCV], excessive alcohol consumption, obesity-related fatty acid
accumulation, environmental toxins, pharmaceutical drugs, and autoimmune disorders.
The liver normally recovers from acute damage with minimal impact on liver function, as
described below, but persistent damage can lead to progressive liver disease. Persistent
damage, such as HBV infection, can lead to inflammation that, if it persists, may lead to
permanent damage and worsen liver function [37]. Chronic alcohol consumption can also
lead to advanced liver disease. In 2017 the mortality rates for alcoholic liver cirrhosis
were 6.8 per 100,000 people [38]. In recent years, obesity rates have been steadily rising,
increasing many obesity-related diseases. Obesity can lead to a condition known as nonalcoholic fatty liver disease (NAFLD), which has rapidly become one of the most
common causes of liver disease in the United States and other western countries. It is
estimated that approximately 31% of adult Americans have some form of NAFLD [39].
Some autoimmune disorders, including autoimmune liver disease, primary sclerosing
cholangitis, and primary biliary cirrhosis, can also cause patients to develop hepatitis that
can further diminish liver function [40]. Immune cells can lose self-tolerance and target
hepatocytes of immunocompromised patients, leading to worsening liver damage if
persistent environmental or internal stimuli continue [41].
5

Liver disease can range in a spectrum of severity. Hepatic steatosis, the initial
stage of liver disease, is hallmarked by lipid accumulation within the hepatocytes [42].
This increase in lipid droplets is associated with developing NAFLD, alcoholic, and druginduced fatty liver disease [42]. Non-alcoholic fatty liver-caused steatosis develops as the
result of multiple factors. The “multi-hit hypothesis” proposes that disease starts with an
accumulation of lipids dependent on insulin resistance development [43]. The first hit
results from insulin resistance and is associated with increases in DNL in the liver leading
to elevated fatty acid production [44]. The secondary hit is when steatosis develops
inflammation, a condition known as steatohepatitis. Oxidative stress is a crucial player in
this second hit, causing the accumulation of proinflammatory cells and activation of
stellate cells, which combine to promote fibrosis [45]. Alcoholic fatty liver disease can
also cause steatosis and steatohepatitis by reducing β-oxidation, increasing fatty acid
synthesis, and reducing fatty acid clearance [46]. Although cases are rare, drug-induced
fatty liver can happen in various ways depending on the drug. Drugs can cause
microvesicular steatosis by reducing β-oxidation, macrovesicular steatosis through
triglyceride accumulation, and drug-induced steatohepatitis by increasing reactive oxygen
species content [47].
Steatosis and steatohepatitis are often asymptomatic and can be reversed if the
damaging agent is eliminated. More recent studies indicate that fibrosis can also be
reversed through the removal of harmful stimuli. However, when damaging stimuli
persist, inflammation and fibrosis can lead to a worsening of liver disease. Fibrosis is
initially triggered by the amassing of inflammatory cells to the liver. These inflammatory
cells produce chemokines, including transforming growth factor-beta (TGF-β), platelet-
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derived growth factor (PDGF), and tumor necrosis factor-alpha (TNF-α), that activate
quiescent hepatic stellate cells [48, 49], which synthesize and secrete extracellular matrix
proteins such as collagen 1a1 (Col1a1) and alpha-smooth muscle actin (α-SMA) [50].
These components contribute to the build-up of fibrotic tissue in the liver. Continued
accumulation of fibrous materials can lead to cirrhosis. Liver cirrhosis, also known as
end-stage liver disease, is not reversible and results in an increased amount of damage
that disrupts the liver’s normal functioning [51]. Cirrhosis is life-threatening, and
although certain drugs can reduce the progression of cirrhosis, the only real treatment is a
liver transplant.
The inflammatory environment of the cirrhotic liver promotes the development of
transformed cells that can lead to cancer. Liver cancer is one of the leading causes of
cancer deaths in the world [52, 53]. Although viral causes of liver cancer are decreasing,
cases associated with NAFLD are dramatically increasing. Hepatocellular carcinoma
(HCC) is a malignancy of the hepatocyte that comprises the most significant amount of
liver cancer cases [54]. Other lesser occurring instances include cancers of
cholangiocytes (cholangiocarcinoma) and blood vessels, but those result in far fewer
cases per year. Cancer of the liver and bile duct rank as the 5th highest cancer death in
American men and 7th in American women in 2021 [55], and liver cancer is projected to
be the second leading cause of cancer deaths by 2030 [56].
The liver is unique among internal organs in that it has the remarkable ability to
regenerate after damage. In times of damage, the liver activates signaling pathways to
restore liver mass. The healthy liver is relatively quiescent, and there is a low level of
hepatocyte loss and renewal. However, hepatocytes can replenish themselves by
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activating signaling systems required for cellular regeneration via the re-entry of
hepatocytes into the cell cycle when there is significant cell loss. In a rodent partial
hepatectomy model, in which 70% of the liver is surgically removed, hepatocytes activate
signaling molecules essential for hepatocyte proliferation, including Notch 1 and
epidermal growth factors (EGF), within an hour [57, 58]. Following hepatocyte
proliferation, the hepatocyte produces growth factors that stimulate angiogenesis and
proliferation of other resident cells of the liver [59]. As a result, the liver can regenerate
to its normal mass in response to the loss of liver cells within 7-10 days.
The liver can also regenerate in response to other models of liver injury, including
those caused by hepatotoxins such as CCl4. These types of liver damage are often zonal
due to the zonal expression of liver enzymes and usually requiring a different
regeneration response than partial hepatectomy. In most liver diseases or after any
hepatocyte damage, regeneration is required. Initially, after damage, the remaining
hepatocytes must receive signals to initiate their re-entry into the cell cycle. Priming the
hepatocytes initializes this proliferation, which results in increased c-jun and c-myc
signaling and production of the inflammatory cytokines TNF-α and interleukin-6 (IL-6)
[60, 61]. This cascade of events enables the transition of quiescent hepatocytes to
proliferative hepatocytes. After the initial priming phase, growth factors, including
hepatocyte growth factor (HGF) and endothelial growth factor (EGF), are released,
causing hepatocytes to enter the cell cycle [62, 63]. Hepatocytes can regenerate to replace
damaged or apoptotic cells and then undergo the termination phase once the liver regains
its normal size. Although there are many unknowns regarding the termination of
hepatocyte regeneration, TGF-β signaling has a role in stopping hepatocyte proliferation
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[64]. Through this multi-phased process, the liver can orchestrate the regeneration and
repair of lost hepatocytes so that the liver can maintain metabolic functions when
regaining normal liver size.
1.4 Models of Liver Disease
Animal models of liver disease have helped to elucidate disease mechanisms and
potential therapeutic treatments, although many experimental models do not fully
recapitulate liver disease in humans. Mouse models for NAFLD focus on either a
genetics-based or a diet-based approach [65]. Alcohol liver disease (ALD) requires the
administration of ethanol orally or through intragastric infusion [66]. One of the most
commonly used liver fibrosis models requires administering the hepatotoxin CCl4. As
noted previously, the metabolism of CCl4 by hepatic Cyp2e1 produces free radicals
causing significant damage and death of hepatocytes. A single dose of CCl4 leads to
transient damage, whereas ongoing treatment over six weeks leads to continual damage
and regeneration and activation of stellate cells, ultimately resulting in fibrosis [67].
Another commonly used fibrosis model is bile duct ligation, a surgical method of liver
damage and fibrosis caused by accumulating bile acids within the liver; an attractive
aspect of this model is that it often mimics human liver disease [68]. Alternatively, diets
used for NAFLD models like Methionine Choline Deficient diet (MCD) and high-fat
(HF) diets can also cause liver damage, including fibrosis [69]. DEN is often used as a
model for HCC, causing DNA damage that results in tumor development [13]. There is
considerable debate in the liver field regarding different animal models and their ability
to fully recapitulate all aspects of liver disease progression in humans.
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1.5 Inbred mouse strains
Mice have been bred for interesting behavioral characteristics and coat colors for
thousands of years [70]. More recently, mice have been bred for phenotypic traits that can
be of use in biomedical research for studying human disease [70]. Through thousands of
years of breeding, many strains and substrains have been developed which can possess
unique characteristics [71] (Figure 1.2). One commonly studied difference between
substrains is the difference between C57BL/6J and C57BL/6N mice. When the
sequencing of these two mice was compared, 34 single nucleotide polymorphisms and 15
structural variants were identified [72]. C57BL/6J mice have a mutation in the
nicotinamide nucleotide transhydronase, which has been found to contribute to impaired
glucose tolerance and insulin secretion [73]. Research characterizing unique phenotypes
between mouse strains can be used as a tool to identify genes that could be involved in
disease.
1.6 Alpha-fetoprotein (AFP)
Alpha-fetoprotein (AFP) is a serum transport protein produced by hepatocytes in
the developing fetal liver; in fact, AFP is the earliest known marker of hepatocytes as
they differentiate from the foregut endoderm during development. AFP is highly similar
in both structure and function to albumin, which is also expressed in the liver and is the
major serum transport protein in adult mammals [53]. Comparisons of albumin and AFP
genes indicate that they are evolutionarily related and have the same structure as other
members of this gene family, which also includes alpha-albumin, Alpha-fetoprotein
related gene, and vitamin D binding protein [74]. In addition to the fetal liver, AFP is
expressed in the yolk sac and, to a lesser extent, in the lower gastrointestinal tract levels
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[75]. AFP is the most abundant protein synthesized in the fetal liver, but its expression
drops off dramatically within the first several weeks after birth [76]. AFP levels typically
remain low in the healthy adult liver, but AFP expression transiently increases in the
regenerating liver after liver damage and is often reactivated in liver cancer, including
HCC. AFP serum levels often correlate with liver disease and HCC severity enabling the
use of serum AFP as an important biomarker. [77]. In most models of toxic liver injury
that requires hepatocyte regeneration, AFP levels were found to significantly increase
[78]. In human cell culture lines, more significant cell proliferation and growth are
associated with increased AFP expression [79]. Furthermore, poorer HCC prognosis and
an increased chance of reoccurrence correlated with higher AFP levels [80]. Studies
investigating AFP expression in the liver have found different mouse strains that have
traits of AFP expression during development and disease, as described further below.
1.7 Alpha-fetoprotein regulator 1 (Afr1)/Zinc fingers and homeoboxes 2 (Zhx2/Afr1)
Due to high AFP levels in HCC, Olsson et al. analyzed serum AFP levels in 27
different strains of inbred mice; this study found that adult BALB/cJ mice had
significantly higher AFP serum levels than all other mouse strains studies, including
several other BALB/c substrains [81]. The elevated AFP levels in the postnatal liver of
BALB/cJ mice were due to a recessive, monogenic trait, and the locus that controlled this
trait was called in called alpha-fetoprotein regulator 1 (Afr1) [81]. After Tilghman and
colleagues cloned the AFP gene, they showed increased liver AFP mRNA levels
correlated with increased serum AFP [82]. Blankenhorn et al. found that the Afr1 locus
was located on mouse Chromosome 15 close to the c-Myc gene [83]. Our lab further
localized Afr1 to a small region of Chromosome 15, and analysis of genes in this region
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found that a hypomorphic mutation in BALB/cJ Zinc fingers and homeoboxes 2 (Zhx2)
gene was responsible for the Afr1 trait [84, 85]. The Zhx2 protein contains two zinc
fingers and four homeodomains, suggesting that it functions as a transcription factor. This
led us to propose that Zhx2 contributes to postnatal silencing of the AFP gene, and the
Zhx2 mutation in BALB/cJ mice results in incomplete AFP repression [84]. In addition to
AFP, Zhx2 represses the expression of other fetal liver genes that are often reactivated in
liver disease and HCC, including Glypican 3 (Gpc3) and the long noncoding RNA
(lncRNA) H19 [84, 86].
Zhx2 mutation serves as a possible candidate for several phenotypic traits that are
seen in BALB/cJ mice (Figure 1.3). The lab of Jake Lusis found that BALB/cJ mice,
when given a high-fat diet, had fewer atherosclerotic plaques than other mouse strains
[87]. This trait, named Hyperlipidemia 2 (Hyplip 2), was mapped by quantitative trait
locus QTL analysis to a region of chromosome 15 where Zhx2 is located. In a
collaboration between our lab and the Lusis lab, it was found that the Zhx2 mutation in
BALB/cJ mice was responsible for the Hyplip2 phenotype [88]. Our lab determined that
BALB/cJ mice, when given a high-fat diet, showed higher lipid content in the liver and
increased inflammation compared to mice with a wild-type Zhx2 gene [89]. These
findings indicate that Zhx2 controls the developmental expression of target genes as well
cardiovascular disease and diet-induced liver injury.
In the chronic CCl4 liver fibrosis model, BALB/cJ mice were found to have
greater liver damage, as judged by fibrotic injury, than other mouse strains [90, 91].
Using QTL analysis, this study concluded that the fibrosis phenotype was associated with
several hepatic fibrosis (Hfib) loci. The most significant QTL, called Hfib1, was
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localized to the same region of chromosome 15 as Zhx2. Since our lab showed that the
Zhx2 gene is mutated in BALB/cJ mice, this led us to hypothesize that Zhx2 is
responsible for the Hfib1 trait and serves as a potential candidate for the increased
fibrosis seen in BALB/cJ mice.
1.8 Alpha-fetoprotein regulator 2 (Afr2)
In an early study of liver regeneration using CCl4, it was found that C3H/HeJ
mice had significantly higher increased AFP expression compared to C57BL/6J [82].
This difference in AFP activation was a monogenic trait governed by a locus called
alpha-fetoprotein regulator 2 (Afr2). The Afr2a allele in C3H/HeJ mice was dominant
over the Afr2b allele found in C57BL/6J mice. Curiously, other genes that are targets of
Zhx2, including H19 and Gpc3, also appear to be regulated by Afr2. The Afr2 locus was
mapped to a region on mouse chromosome 2 [92], although it should be noted that this
study, in contrast to earlier studies, suggested that the Afr2a and Afr2b alleles were codominant. Several candidate genes for Afr2 fall within this region of Chromosome 2
(Figure 1.4), but it is currently unknown what gene is responsible for the Afr2 phenotype.
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Figure 1.1 Liver Structure and Function.
(A). Layout of the liver lobule with six portal triads surrounding a single central vein.
Hepatocytes in the lobule are located in zone 1 (periportal region), zone 2, or zone 3
(pericentral region (B). Labeled image of how the liver lobule works, with blood flowing
from portal vein/hepatic artery, past the major cells of the liver, to the central vein; bile
flows in the opposite direction and exits the liver through the bile duct. Created with
BioRender.com
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Figure 1.2 Phylogenetic tree of inbred mouse strains.
Figure from Petkov PM, Ding Y, Cassell MA, Zhang W, Wagner G, Sargent EE, Asquith
S, Crew V, Johnson KA, Robinson P, Scott VE, Wiles MV. An efficient SNP system for
mouse genome scanning and elucidating strain relationships. Genome Res. 2004
Sep;14(9):1806-11. doi: 10.1101/gr.2825804. PMID: 15342563; PMCID: PMC515327.

15

Figure 1.3 The Zhx2 gene co-localizes with several traits that are seen in BALB/cJ
mice.
Quantitative trait analysis (QTL) mapping of the Zhx2/Afr1 interval responsible for
increased AFP levels in BALB/cJ mice to a region on mouse chromosome 15 (green).
Other phenotypic traits, including Hyplip2 (Blue), Hfib1 (Orange), and Male aggression
(Gray), have been mapped to intervals overlapping the Zhx2 mutation. Created with
BioRender.com.
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Figure 1.4 Mapping of Afr2 interval on chromosome 2.
Quantitative trait analysis (QTL) mapping of the Afr2 interval responsible for differing
AFP reactivation responses in liver regeneration in C3H/HeJ and C57BL/6J mice to a
region on mouse chromosome 2 (Purple). Created with BioRender.com
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CHAPTER 2. MATERIALS AND METHODS
2.1 Mice
Mice were housed in the University of Kentucky Division of Laboratory Animal
Research (DLAR) facility and were kept according to approved Institutional Animal Care
and Use Committee (IACUC) protocols. Mice were purchased from The Jackson
Laboratory, obtained from the Knockout Mouse Project (KOMP), or bred in-house. The
mice were maintained on a 14/10 light/dark cycle and had access to ad libitum food and
water.
2.2 Generating BALBcJAfr1/Afr1 and BALBcJWT/Afr1 mice
Male BALB/cJ mice, homozygous for the Zhx2Afr1 allele, were bred to female
BALB/cByJ mice that were homozygous for wildtype Zhx2 allele (Zhx2WT). Female
offspring of this mating (BALB/cJWT/Afr1) were backcrossed to male BALB/cJ mice to
obtain male and female BALB/cJAfr1/Afr1 and BALB/cJWT /Afr1 F2 offspring. At 8-weeks of
age, F2 mice were administered carbon tetrachloride (CCl4) injections as described below.
2.3 Generating Zhx2WT/Afr1 and Zhx2KO/Afr1 mice
Zhx2Fl/Fl mice were initially purchased from the Knockout Mouse Project
Repository (KOMP) at the University of California- Davis. These mice had loxP sites
flanking Zhx2 exon 3, which contains the entire Zhx2 protein-coding region. When exon
three was deleted, it resulted in a complete deletion of the Zhx2 protein. Male BALB/cJ
mice (BALB/cJAfr1) were bred to C57BL/6 mice heterozygous for the null mutation in the
Zhx2 gene (Zhx2WT/KO) to obtain male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 offspring.
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Mice were maintained until 8-weeks of age before starting CCl4 injections as described
below.
2.4 Afr2 Pilot Study
Male mice from six strains: 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J,
C57BL/6NJ, and C57BL/10SnJ were obtained from the Jackson Laboratory and used to
determine AFP activation during liver regeneration. Mice were maintained until 6-weeks
of age before receiving a single dose of CCl4 or mineral oil (MO), as described below.
2.5 Generating 129x1SvJxBL/6J
Breeding pairs of 129X1/SvJ and C57BL/6J mice were set up to generate male
and female F1 offspring. Mice were maintained until 8-weeks of age before receiving a
CCl4 or MO injection.
2.6 Genotyping
When pups were approximately 14 days of age, mice were ear-tagged for
experimental identification, and the removed ear skin was digested overnight at 55°C in
500 µL of tail lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM
NaCl, 100 µg/mL Proteinase K). After digestion, samples were briefly vortexed, 500 µL
of isopropanol was added, and samples were thoroughly mixed to precipitate the DNA.
The DNA was pelleted by centrifugation at 13,000 g for 5 minutes, and the supernatant
was decanted. The pellet was then washed with 500 µL of 75% EtOH and centrifuged at
13,000 g for 5 minutes, and the supernatant was again decanted. Tubes were inverted on a
paper towel to dry for 30 minutes. Pellets were resuspended in 100 µL sterile ddH2O. For
BALB/cJ genotyping, 2 µL of DNA was added to a PCR mixture including 10 µL 2x
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Dream Taq (Thermo Scientific), 7.4 µL of ddH2O, 0.3 µL of the forward primer, and 0.3
µL of the reverse primer. Three PCR reactions were used to determine BALB/cJ
genotyping by pairing primers for Afr1 and ETn3Flank to determine BALB/cJWT (no
product for BALB/cJAfr1, amplicon 392 bp for BALB/cJWT), Afr1, and Afr2 to determine
BALB/cJAfr1 (amplicon 269 bp for BALB/cJAfr1, no product for BALB/cJWT), and
ETn3Flank and Afr3 to determine BALB/cJAfr1 (amplicon 786 bp for BALB/cJAfr1, no
product for BALB/cJWT). For Zhx2 genotyping, 2 µl of DNA was added to a PCR
mixture, including 10 µL of 2x Dream Taq (Thermo Scientific), 0.3 µL of Zhx25F
primer, 0.3 µL of LAR3 primer, and 0.3 µL Zhx25R primer, and 7.1 µL water. The
amplicons for Zhx2 genotyping will be 230 bp for the Zhx2 floxed allele (Zhx2KO) and
385 bp for the wild-type Zhx2 allele (Zhx2WT). Samples for BALB/cJ and Zhx2
genotyping underwent the same PCR protocol: 95°C for 3 minutes, 40 cycles of 95°C for
30 seconds, 55°C for 30 seconds, and 72°C for 40 seconds, and a final 72°C for 5
minutes. Primer sequences are listed in Table 2.1. The resulting product was mixed with
5 µL of 6x loading dye, and 10 µl was loaded on a 1% agarose gel along with 3ul of
Gene Ruler 100bp Plus (Thermo Scientific). Samples were run at 150V for 30 minutes
and visualized using an Amersham Imager 600 (GE).
2.7 Model for liver fibrosis (CCl4)
At eight weeks of age, mice were selected to be injected intraperitoneally with 0.5
mL/kg of carbon tetrachloride (CCl4) that was diluted 1:10 in mineral oil; control mice
received mineral oil (MO) alone, prepared weekly. Each injection was performed with a
28G insulin syringe (Becton Dickinson). Mice were injected twice weekly for a total of 6
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weeks (12 injections). Forty-eight hours after the final injection, at 7:00 AM, unfasted
mice were euthanized.
2.8 Model for acute liver damage and regeneration (CCl4)
When mice were at 6 or 8 weeks of age, mice were injected intraperitoneally with
50 µL of a solution containing 2.5mg/kg CCl4 dissolved in MO or MO alone, as
described above. Seventy-two hours after injection, at 10:00 AM, unfasted mice were
euthanized.
2.9 Euthanasia and Tissue Collection
At the end of each animal study, individual mice were weighed and euthanized in
a CO2 chamber (30-70% cage volume/minute), followed by cervical dislocation. Blood
was collected by cardiac puncture using a 1mL syringe with a 26G needle and allowed to
clot for approximately one hour. Serum was obtained by centrifuging the blood sample at
13,000g for 3 minutes, and the clear supernatant was transferred to a new tube. The
mouse liver was excised from the abdominal cavity, weighed, and cut into smaller
sections. Sections were selected and placed in a cassette and placed in formalin for 3
days. After 3 days, cassettes were briefly washed in ddH2O and stored in 70% ethanol
until being paraffin-embedded. Liver sections were also frozen at -80°C in OCT for
sectioning or frozen at -80°C in tubes for RNA and DNA extraction.
2.10 RNA extraction/cDNA/qPCR
Frozen liver sections that were stored at -80°C were weighed before RNA
extraction. Tissue samples (~50 mg) were homogenized using a pestle in 200 µl RNAzol
(Molecular Research Center Inc.). An additional 800 µL of RNAzol was added and
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pipetted to mix. Sterile ddH2O (400 µL) was added to the mixture, which was then mixed
vigorously for 15 seconds. After incubation at room temperature for 15 minutes, the
samples were centrifuged at 13,000 g for 15 minutes at 4°C. After centrifuging, the
sample tubes contained clear supernatant and a dark pellet. Careful to not disturb the
pellet, the supernatant (1.2 mL) was transferred to two tubes (600 µL/tube), followed by
the addition of equal parts of isopropanol. The solution was mixed and stored at 4°C for
approximately 1 hour, followed by centrifugation at 13,000 g for 10 minutes, and the
supernatant was decanted. The resulting pellet was washed twice with 75% ethanol,
centrifuged at 8,000 g for 5 minutes, and decanting ethanol in between washes. The pellet
was dried for approximately 15-30 minutes, and the RNA pellet was dissolved in sterile
100 to 200 µL of ddH2O. RNA concentrations were determined using a Nanodrop
(Thermo Scientific). An aliquot of RNA was added to sterile ddH2O to obtain a final
RNA concentration of 1 ug/10µl of ddH2O. RNA was converted into cDNA using HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). RNA (1 µg/10µL) was
combined with 2 µL of 10x buffer, 2 µl of random primers, 0.8 µL dNTPs, 1 µL of
reverse transcriptase, and 4.2 µL of ddH2O. The mixture was placed into 0.2 mL PCR
tubes and subjected to the following PCR using a SimpliAmp Thermal Cycler (Applied
Biosystems): 25°C for 10 minutes, 37°C for 2 hours, 85°C for 5 minutes. Quantitative
Real-Time PCR (qPCR) assays were conducted using the following reagents: 10 µL of
SYBR Green PCR Supermix (Bio-Rad), 0.5 µL of 10 µM forward and reverse primers, 8
µL sterile ddH2O, and 1 µL cDNA. qPCR was conducted using the CFX96 Real-Time
System (Bio-Rad) and was subjected for the following PCR: 95°C for 3 minutes, 40
cycles of 95°C for 10 seconds and 60°C for 45 seconds, followed by a melt curve, and

22

analyzed using the CFX Manager software (Bio-Rad). Oligonucleotide primer sequences
are listed in Table 2.2. Transcript CT values were normalized to serine/arginine-rich
splicing factor 4 (SFRS4), a splicing factor and housekeeping gene, and analyzed using
the ΔΔCT method [93]. SFRS4 has been found to be a more consistently expressed
housekeeping gene compared to GAPDH in advanced liver diseases like HCC [94].
2.11 Histology
All histology was performed by the COBRE Pathology Research core or the
Markey Cancer Center Biospecimen Procurement and Translational Pathology Shared
Resource Facility. Formalin-fixed tissue samples were paraffin-embedded. Paraffinembedded blocks were cut at 6-micron thickness on a microtome. Sections were adhered
to slides and stained for Hematoxylin and Eosin, Sirius Red, or Masson Trichrome. Sirius
Red was used for staining collagen and amyloid [95] and Masson Trichrome stains type I
collagen [96]. Sirius red staining has been shown to have red fluorescence [97]. Sirius
Red was quantified by using fluorescent microscopy and analyzed on ImageJ using mean
fluorescence measurement.
2.12 TGF-β ELISA
Serum TGF-β levels were determined using the R&D Systems Quantikine ELISA
TGF-β kit (DB100B) per the manufacturer’s instructions. Serum samples were first
activated by adding 40 µL of serum to a polypropylene tube along with 20 µL of 1N
HCL. The sample was mixed and incubated for 10 minutes at room temperature. Samples
were then neutralized by adding 20 µL of 1.2 N NaOH/0.5 M HEPES and mixed. After
neutralization, the samples were further diluted with calibrator diluent: 40-fold dilution
for mineral oil samples (5 µL in 195 µL) or 80-fold dilution for CCl4 samples (2.5 µL in
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197.5 µL). The ELISA plate was loaded with 50 µL of assay diluent and 50 µL of
standard, controls, and activated samples. The plate was gently mixed, covered, and
incubated at room temperature for two hours. After incubation, the ELISA plate was
aspirated and washed four times with wash buffer, blotting on paper towels in between.
After washing, 100 µL of TGF-β conjugate was added to each well, covered, and
incubated for two hours at room temperature. The plates were then washed four times
with wash buffer, blotting on paper towels in between. After the plate was blotted dry,
100 µL of the substrate solution was added, and the plate was protected from light for 30
minutes for color development. One hundred microliters of stop solution were added to
each well to block further color development, and the optical density was measured at
450 nm and 560 nm as wavelength correction. The concentrations were calculated based
on the standard curve and then multiplied by their dilution factor.
2.13 ALT Assay
Serum Alanine Aminotransferase (ALT) levels were assessed using an Alanine
Aminotransferase Activity Kit (Sigma Aldrich) per the manufacturer’s instructions.
Samples were prepared by diluting 10 µL of MO-treated serum samples in 10 µL of ALT
Assay Buffer or 5 µL of CCl4-treated serum samples in 15 µL of ALT Assay Buffer into
a 96-well microplate. This was followed by the addition of 100 µL of master reaction mix
(86 µL ALT Assay Buffer, 2 µL Fluorescent Peroxidase Substrate, 2 µL ALT Enzyme
Mix, 10 µL ALT Substrate). Samples were protected from light and incubated at room
temperature for 3 minutes, followed by an initial reading at 560 nm. Samples were then
incubated at 37°C and read again after 2, 5, 8, and 10 minutes. The final reading is the
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last reading in which none of the samples exceed the standard curve. Calculations to
determine ALT levels were performed as per the manufacturer’s instructions.
2.14 AFP ELISA
Alpha-fetoprotein (AFP) serum levels were measured using the R&D Systems
Quantikine ELISA Alpha-fetoprotein/AFP kit (MAFP00) according to the manufacturer’s
instructions. Serum samples were diluted 200-fold in calibrator diluent before use in the
ELISA. Fifty microliters of assay diluent were added to the plate along with 50 µL of
standard or diluted sample. The plate was covered and incubated at room temperature for
2 hours on a horizontal orbital microplate shaker at 500 rpm. After incubation, wells were
aspirated and washed four times with wash buffer, blotting dry on paper towels between
each wash. After the final blotting, 100 µL of Mouse AFP conjugate was added, and the
plate was incubated for 2 hours at room temperature on the horizontal orbital microplate
shaker. The plate was then aspirated and washed four times with wash buffer, blotting dry
on paper towels between each wash. Next, 100 µL of substrate solution was added, and
the plate was protected from light for 30 minutes as the color developed. To stop color
development, 100 µL of stop solution was added to each well, and the optical density was
read at 450nm and 560nm for wavelength correction. The concentrations were calculated
based on the standard curve and multiplied by 200 to determine AFP levels in the
undiluted serum samples.
2.15 Hydroxyproline
Hydroxyproline assays were conducted using the Hydroxyproline Colorimetric
Assay Kit (BioVision). Samples were prepared by homogenizing 10mg of frozen liver
tissue in 100 µL of ddH2O. Tissue homogenate (~100 µL) was added to a glass tube with
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a Teflon-lined cap, and 100 µL of concentrated HCl (12N) was added. The samples were
hydrolyzed for 3 hours at 120°C. After hydrolysis, 40 µL of sample and the standard per
manufacturer’s instructions was added to a transparent flat-bottomed 96-well plate and
dried in a 60°C oven for approximately 1 hour. While drying, hydroxyproline kit reagents
were warmed to room temperature, and both the Chloramine T reagent and DMAB
Reagent were prepared per the manufacturer’s instructions. Chloramine T reagent (100
µL) was added to each standard and sample well and incubated at room temperature for 5
minutes. DMAB reagent (100 µL) was then added to each well. The plate was covered
and incubated at 60°C for 1.5 hours. The plate was read on the GloMax Microplate reader
(Promega) at 560 nm. The concentration was determined using the standard curve and
calculated using the manufacturer’s instructions.
2.16 Statistics
All data is represented as a mean +/- standard deviation. Descriptive statistics and
Normality tests were performed on each data set using GraphPad Prism 9. A two-tailed ttest or one-way ANOVA with multiple comparisons of means was calculated using
GraphPad Prism 9 when appropriate. Post-hoc tests were selected based on the
distribution of the data. A p-value of less than 0.05 was considered significant. Outliers
were detected using Grubbs’ test using GraphPad Prism outlier calculator and not
included in analysis.
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Figure 2.1 Breeding schematic for the Hfib1 project.
BALB/cJ mice that were homozygous for the Afr1 mutation were bred to F1 mice
(BALB/cJAfr1/Afr1x BALB/cByJWT/WT) to obtain male and female mice that express
normal Zhx2 levels (BALBcJWT/Afr1) and low Zhx2 levels (BALB/cJAfr1/Afr1) (A).
BALB/cJ mice that were homozygous for the Afr1 mutation were bred to heterozygous
Zhx2WT/KO on a C57BL/6J background to obtain male and female mice that express
normal Zhx2 levels (Zhx2WT/Afr1) and low Zhx2 levels (Zhx2KO/Afr1) (B). Created on
BioRender.com
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Figure 2.2 Experimental design for the Hfib1 study.
Mice selected for the Hfib1 experiment were maintained for 8 weeks until the start of the
injection series. Mice were then given either mineral oil or CCl4 twice weekly for 6 weeks.
Forty-eight hours after the last injection, mice were euthanized, and tissues were collected.
Created on BioRender.com
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Figure 2.3 Experimental design for Afr2 pilot study.
Male mice from six mouse strains (129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/10SnJ,
C57BL/6NJ, and C57BL/6J) were injected once with either mineral oil or CCl4. After 72
hours, mice were euthanized, and tissue was collected. Created on BioRender.com
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Figure 2.4 Experimental design for Afr2 full liver regeneration study.
129X1/SvJ, C57BL/6J, and F1 male and female mice were injected once with either
mineral oil or CCl4. After 72 hours, mice were euthanized, and tissue was collected.
Created on BioRender.com
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Table 2.1 Primers used for genotyping
Primer
Number
1651
1652
1654
1043
1044
1045
1259

Gene
Zhx25F
LAR3
Zhx25R
Afr1
Afr2
Afr3

Sequence
5’ GGACCGAATCTCACTATTTAACTCA
5'ACAACGGGTTCTTCTGTTAGTCC
5’ AGGCTGGCAGTGGGTTAGAAA
5’ AACCCAAGTAGCAAGTGAGTGGTG
5’ AACCCAAGTAGCAAGTGAGTGGTG
5’ ATCTCTGGTCCAGTAGAAAGGTGC
ETn3Flank 5’ CCTATCTTGGTACCCTGATCAAGC

Primer number, gene names, and sequences of primers used for genotyping experimental
mice.
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Table 2.2 Primers used for gene expression analysis
Primer
Number
1688
1689
1588
1589
1806
1807
2393
2394
1775
1776
2624
2625
1590
1591
1130
1131
1604
1605
1031
1032
1524
1525

Gene
SFRS4f
SFRS4r
Zhx2
Zhx2R
Col1a1f
Col1a1r
mCola1f
mCola1r
SMAf
SMAr
mTimp1 F
mTimp1 R
AFPrtF
AFPrtR
H19Ex2‐U2
H19Ex3‐L3
LplrtF
LplrtR
Gpc3URT
Gpc3LRT
Cyp2E1F
Cyp2E1R

Sequence
5’ CTCGCACAGAGTACAGACTTAT
5’ TTGCGTCCCTTGTGAGCATCT
5’ GGACCGATATGATGCTTCCTGG
5’ CGTTCAGGTTTTGCGTGGAGT
5’ CATAAAGGGTCATCGTGGCT
5’ TTGAGTCCGTCTTTGCCAG
5' ACATGTTCAGCTTTGTGGACC
5' TAGGCCATTGTGTATGCAGC
5’ GTCCCAGACATCAGGGAGTAA
5' TCGGATACTTCAGCGTCAGGA
5' CCCTTCGCATGGACATTTA
5' AGATGCCAGAGATGCAAAG
5'CCGGAAGCCACCGAGGAGGA
5'TGGGACAGAGGCCGGAGCAG
5'GGAGAGGACAGAAGGGCAGT
5'GTTCAAGGTAGGGGGAGGAG
5'TGGCTACACCAAGCTGGTGGGA
5'GGTGGACGTTGTCTAGGGGGTAGT
5'CTCCCAAGCAACGCCAATATAGAT
5'CTGATTCTTCATCCCGTTCCTTGC
5'CAAGTCTTTAACCAAGTTGGCAAA
5'CCACGATGCGCCTCTGA

Primer number, gene names, and sequences of primers used in qPCR gene expression
analysis.
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CHAPTER 3. THE INCREASED FIBROSIS PHENOTYPE, HFIB1, IN BALB/CJ
MICE IS NOT DUE TO THE MUTATION IN ZHX2 (AFR1)
3.1 Introduction
Liver disease prevalence has a significant clinical impact, being the cause of two
million deaths globally in 2010, with one million of those being due to liver cirrhosis
[98]. Liver fibrosis and cirrhosis occur when harmful stimuli cause persistent damage,
resulting in the production of extracellular matrix proteins. Fibrotic accumulation within
the liver is initially triggered by hepatocyte damage. Studies have shown that in the case
of lipotoxic injury, hepatocytes increase the release of vesicles that contains tumor
necrosis factor apoptosis ligand (TRAIL), which activates macrophages [99]. These
inflammatory cells then produce and release chemokines, including TGF-β, PDGF, and
TNF-α [48, 49]. These chemokines bind to specific receptors on hepatic stellate cells to
cause activation and promote the transition to myofibroblasts [100]. The activated
extracellular matrix cells produce collagen 1a1 and α-SMA, contributing to the build-up
of fibrosis in the liver [50]. As fibrotic tissue continues to accumulate in the liver, the
organ may become cirrhotic, resulting in an increased amount of irreparable damage that
disrupts the liver’s normal functioning [51].
One specific mouse substrain, BALB/cJ, has been found to display several unique
phenotypic traits. BALB/cJ mice exhibit persistent expression of fetal liver genes into
adulthood [82, 84]. This trait is due to a hypomorphic mutation in the gene Zinc fingers
and homeoboxes 2 (Zhx2), located on chromosome 15, leading to significantly lower
Zhx2 protein levels [82, 84]. BALB/cJ mice also display reduced atherosclerotic plaques
than other mouse strains when fed a high-fat diet [87]. QTL analysis determined that this
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trait, named Hyperlipidemia2 (Hyplip2), mapped to the same region on chromosome 15
as Zhx2. Further research using Zhx2 transgenic BALB/cJ mice determined that the Zhx2
mutation was responsible for the reduced atherosclerotic phenotype in BALB/cJ mice
[88]. Although there were reductions in cardiovascular disease using the high-fat diet
model, studies in our lab demonstrated that there was increased liver pathophysiology,
including increased lipid accumulation and inflammation, in BALB/cJ mice fed a high-fat
diet; this liver phenotype is due to the Zhx2 mutation [89]. Other traits in BALB/cJ mice,
including altered expression of numerous Cyp and Major urinary proteins (Mup) genes,
are due to the Zhx2 mutation in this strain [101, 102].
A screen for differences in liver fibrosis in a panel of mouse strains indicated that
BALB/cJ mice exhibit increased liver fibrosis in a chemical-induced model of chronic
liver damage. In this CCl4 model, BALB/cJ mice were shown to have increased fibrotic
histology and hydroxyproline levels compared to A/J and FVB/N mice [90, 91]. These
studies found that when BALB/cJ mice were crossed with these other strains, the
offspring had reduced fibrosis, indicative of a recessive mutation. QTL analysis revealed
several loci that controlled increased fibrosis in BALB/cJ mice. The strongest of these
QTLs, named Hepatic fibrosis 1 (Hfib1), mapped to the same region of chromosome 15
as Zhx2.
Although the Hfib1 region overlaps with Zhx2, the gene responsible for Hfib1 is
unknown. Considering both the overlap of the Hfib1 interval with Zhx2 and the effect
Zhx2 has on several liver phenotypes in BALB/cJ mice, we hypothesize that the Zhx2
mutation is responsible for the Hfib1 fibrosis phenotype in this mouse strain. To directly
test this, I performed two complementation experiments using the chronic CCl4-treated
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liver fibrosis model. Although we hypothesized that there would be a difference in
fibrosis markers between mice that did or did not express Zhx2, we observed no
significant differences in fibrosis. This finding eliminates Zhx2 as a candidate Hfib1 gene
and suggests that there is another gene in this region responsible for the increased fibrosis
phenotype.
3.2 Results
As described in chapter 2, our lab obtained mice with a floxed allele of the Zhx2
gene from the KOMP. We have crossed this allele to C57BL/6J and to mice with the
actin-Cre transgene to delete Zhx2 exon 3 in all cells; the deleted allele will be referred
to as Zhx2KO.
Two complementation studies were performed. First, BALB/cJ mice
(BALB/cJAfr1/Afr1) were bred to Zhx2WT/KO mice to generate offspring that were
Zhx2Afr1/WT or Zhx2Afr1/KO. We also bred BALB/cJ mice to BALB/cByJ, which is highly
related to BALB/cJ but has a wild-type Zhx2 gene to obtain an F1. These F1 offspring
were backcrossed to BALB/cJ to obtain F2 offspring that were BALB/cJAfr1/WT or
BALB/cJAfr1/Afr1. PCR of genomic DNA was used to confirm the Zhx2 alleles in
experimental animals. At 8 weeks of age, mice from each genotype received either MO
or CCl4 twice weekly for 6 weeks. Forty-eight hours after the final injection, livers and
serum were collected. Analysis of liver RNA in both studies confirmed that Zhx2 mRNA
levels in both male and female Zhx2KO/Afr1 and BALB/cJAfr1/Afr1 mice were dramatically
lower than Zhx2 levels in Zhx2WT/Afr1 and BALB/cJWT/Afr1 littermates (Fig. 3.1 A-D).
Zhx2 expression in male and female mice from both cohorts did not significantly change
due to CCl4 treatment (Fig. 3.1A-D).
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With confirmation that Zhx2 expression was reduced in these mice as expected,
liver damage was assessed using histological staining. The overall liver damage and
fibrosis observed in CCl4-treated mice was assessed using hematoxylin & eosin, Masson
trichrome, and Sirius red staining (Fig. 3.2 A-D). Although it was seen that CCl4-treated
mice displayed increased liver damage and fibrosis, histological results show that
differences in Zhx2 expression did not alter the fibrosis levels, as determined
histologically, when mice were treated chronically with CCl4 (Fig. 3.2 A-D). Initial
quantification of Sirius Red staining revealed no significant difference in average
fluorescence except female Zhx2KO/Afr1 when compared to Zhx2WT/Afr1 treated with CCl4
(Figure 3.3 A-D). These results will further need to be confirmed by a pathologist and
quantified using fluorescent microscopy.
In addition to histological assessment, mRNA expression levels of fibrosis
markers associated with fibrosis were also analyzed. Alpha smooth muscle actin (Gene:
ACTA2) mRNA expression levels were found to be substantially higher in CCl4-treated
compared to MO-treated mice in male and female mice of both cohorts (Fig. 3.4 A-D). A
similar pattern was observed when Collagen1a1 mRNA levels were analyzed; levels
increased in both male and female CCl4-treated mice compared to MO controls but were
not affected by Zhx2 levels (Fig 3.5. A-D). Timp1, which regulates matrix
metalloproteinases, was also analyzed. Timp1 mRNA levels also increased in CCl4treated mice but were not affected by Zhx2 levels (Fig. 3.6 A-D). Hydroxyproline is a
major component of collagen and can be used to measure collagen levels [103]. In
previous studies identifying the Hfib1 region, hydroxyproline has been used as a marker
of fibrosis [90]. Hydroxyproline levels were also assessed in these experimental mice
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using a colorimetric kit, showing no significant changes regardless of treatment or Zhx2
expression (Figure 3.7).
Increased inflammation is a hallmark of liver disease, including liver fibrosis. We,
therefore looked at several inflammatory cytokines in these experimental mice. Levels of
Tumor Necrosis Factor α (TNFα) and Transforming Growth Factor-β (TGF-β) were
assessed in all groups. In Zhx2WT/Afr1 and Zhx2KO/Afr1 mice, TNFα mRNA levels only
differed between Zhx2KO/Afr1 CCl4 and MO-treated male mice (Fig. 3.8 A-B). In
BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice, there were no significant changes in TNFα
expression regardless of treatment or sex (Fig. 3.8 C-D). However, TGF-β mRNA levels
were higher in the male and female Zhx2WT/Afr1, Zhx2KO/Afr1, BALB/cJWT/Afr1, and
BALB/cJAfr1/Afr1 mice treated with CCl4 than MO-treated mice, but only significantly in
male and female Zhx2WT/Afr1, male Zhx2KO/Afr1, and male BALB/cJAfr1/Afr1 (Fig. 3.9 A-D).
Zhx2 expression did not significantly change TGF-β mRNA levels. Serum levels of TGFβ were assessed using ELISA. Regardless of treatment or Zhx2 expression, TGF-β levels
did not significantly differ for all mice (Fig. 3.10 A-D).
In addition to assessing fibrosis and inflammation, mouse serum was analyzed for
alanine aminotransferase (ALT) levels. ALT levels serve as a serum biomarker for liver
damage, being released from damaged hepatocytes into the bloodstream [104]. When the
mouse serum was assayed for ALT levels, male and female Zhx2WT/Afr1 and Zhx2KO/Afr1
mice treated with CCl4 had significantly higher ALT levels than mice treated with MO
(Fig. 3.11 A-B). Male BALBcJWT/Afr1 and BALBcJAfr1/Afr1 treated with CCl4 also have
significantly higher ALT levels than mineral oil-treated (Fig. 3.11 C). Unexpectedly,
Female BALBcJWT/Afr1 and BALBcJAfr1/Afr1 treated with mineral oil had significantly
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higher ALT levels than the CCl4-treated mice (Fig. 3.11 D). There was no significant
difference in ALT levels regardless of Zhx2 expression in male or female mice.
3.3 Discussion
Studies described in this chapter tested the hypothesis that Zhx2 was responsible
for the Hfib1 phenotype that was previously described in BALB/cJ mice. We used two
genetic complementation approaches to test this directly. The first used BALB/cJ and
C57BL/6J mice that have a null mutation in the Zhx2 gene. The second was a cross
between two highly related BALB/c substrains, one with a hypomorphic Zhx2 mutation
(BALB/cJ) and the second with a wild-type Zhx2 gene (BALB/cBYJ). Analysis of
mRNA levels confirmed that dramatically reduced Zhx2 levels were observed in
Zhx2Afr1/Afr1 and Zhx2Afr1/KO mice compared to their Zhx2Afr1/WT littermates in both
cohorts. Chronic CCl4 treatment did promote fibrosis in male and female mice in both
cohorts as determined by histological analysis, expression of the fibrotic genes ACTA2,
Col1a1 and TIMP1, TGF and TNF levels, and serum ALT levels. However, the
presence or absence of Zhx2 did not impact the severity of fibrosis as judged by these
markers. Based on these results, we were not surprised that liver hydroxyproline levels
were not affected by the absence of Zhx2. However, we did anticipate that
hydroxyproline levels would be higher in CCl4 treated mice than in MO controls and
cannot explain why there were no differences in these two treatment groups. Since there
are noticeable differences in liver histology, it is possible that the assay was not sensitive
enough to determine changes in hydroxyproline levels within the livers of control and
treated mice.
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Data from this study indicate that the Afr1 mutation in Zhx2 is not responsible for
the Hfib1 phenotype. This would suggest that another candidate gene within the Hfib1
region could account for the Hfib1 trait. This region houses several genes involved in
liver disease, including Tnfrsf11b, Colec10, DEPTOR, A1bg, Col14a1, and Has2.
Tnfrsf11b, or osteoprotegerin, was reduced in the circulating serum in individuals with
NAFLD [105]. In HCC, collectin liver 1 (Colec10) and alpha-1-beta glycoprotein (A1bg)
were found to be reduced [106] [107]. Poorer prognosis in HCC has also been linked to
the expression of the inhibitor of mTOR signaling DEPTOR [108]. Increases in both
collagen 14a1 (Col14a1) and hyaluronan synthase 2 (Has2) have been found in liver
fibrosis [109, 110]. Further experiments looking at the expression of, or polymorphisms
within, these other genes could be analyzed to determine if any are viable candidates for
Hfib1. Additionally, the CCl4 data from this experiment is highly variable, which might
make any slight difference we see between the wild-type and Zhx2 deficient mice from
reaching significance. Modifications in CCl4 administration or altering the fibrosis model
might lead to more consistent results.
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Figure 3.1 Mice homozygous for the Zhx2Afr1 mutation or heterozygous Zhx2Afr1/KO
mice display reduced Zhx2 mRNA levels.
Zhx2 mRNA expression in male Zhx2WT/Afr1 (n=6) or Zhx2Afr1/Afr1 mice (CCl4 n=5, MO
n=6), treated with either CCl4 or MO (A). Zhx2 mRNA expression in female Zhx2WT/Afr1
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(CCl4 n=5, MO n=6) or Zhx2Afr1/Afr1 mice (CCl4 n=5, MO n=4), treated with either CCl4
or MO (B). Zhx2 mRNA expression in male BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) or
BALB/cJAfr1/Afr1 mice (n=6), treated with CCl4 or MO (C). Zhx2 mRNA expression levels
in female BALB/cJWT/Afr1 (n=5) or BALB/cJAfr1/Afr1 mice (CCl4 n=5, MO n=6) (D).
*p<0.05, **p<0.01.
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Figure 3.2 Histological analysis indicates that reduced Zhx2 expression does not
alter fibrosis after CCl4 treatment.
Representative histology (10x) from male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 mice
(A, B) and male and female BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice (C, D) with either
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WT or reduced Zhx2, treated with CCl4 or MO for six weeks. Images shown are
Hematoxylin and Eosin (Top), Masson Trichrome (Middle), and Sirius Red (Bottom).
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Figure 3.3 Sirius Red quantification indicates that Zhx2 expression does not alter
fibrosis after CCl4 treatment.
Histology (10x) from male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 mice and
BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice treated with CCl4 or MO for six weeks were
imaged for red fluorescence. Images were quantified using ImageJ. Sirius Red
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fluorescence was quantified in male Zhx2WT/Afr1 (MO n=5, CCl4 n=6 ) or Zhx2KO/Afr1
(n=6) mice, treated with CCl4 or MO (A). Sirius Red fluorescence was quantified in
female Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 mice (MO n=4, CCl4 n=5), treated with CCl4 or
MO (B). Sirius Red fluorescence was quantified in male BALB/cJAfr1/Afr1 (n=6) or
BALB/cJWT/Afr1 (n=5) mice treated with CCl4 or MO (C). Sirius Red fluorescence was
quantified in female BALB/cJAfr1/Afr1 (MO n=6, CCl4 n=5) or BALB/cJWT/Afr1 (n=5) mice,
treated with CCl4 or MO (D). *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.4 CCl4-mediated increase in ACTA2 mRNA levels are not altered by the
absence of Zhx2.
ACTA2 mRNA expression in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 or
MO (n=6) (A). ACTA2 mRNA expression in female Zhx2WT/Afr1 (CCl4 n=5, MO n=4) or
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Zhx2KO/Afr1 mice (n=4), treated with CCl4 or MO (B). ACTA2 mRNA expression in male
BALBcJAfr1/Afr1 (CCl4 n=6, MO n=5) or BALB/cJWT/Afr1 (n=6) mice, treated with CCl4 or
MO (C). ACTA2 mRNA expression in female BALB/cJAfr1/Afr1 (CCl4 n=4, MO n=6) or
BALB/cJWT/Afr1 (CCl4 n=5, MO n=4) mice, treated with CCl4 or MO (D). *p<0.05.
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Figure 3.5 CCl4-mediated increase in Col1a1 mRNA levels are not altered by the
absence of Zhx2.
Col1a1 mRNA expression in male Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 mice (CCl4 n=5, MO
n=6), treated with CCl4 or MO (A). Col1a1 mRNA expression in female Zhx2WT/Afr1
(CCl4 n=6, MO n=5) or Zhx2KO/Afr1 mice (CCl4 n=5, MO n=4), treated with CCl4 or MO
(B). Col1a1 mRNA expression in male BALBcJAfr1/Afr1 (CCl4 n=6, MO n=5) or
BALB/cJWT/Afr1 mice (CCl4 n=6, MO n=5), treated with CCl4 or MO (C). Col1a1 mRNA
expression in female BALB/cJAfr1/Afr1 (CCl4 n=4, MO n=6) or BALBcJWT/Afr1 mice (CCl4
n=4, MO n=5), treated with CCl4 or MO (D). *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.6 CCl4-mediated increase in Timp1 mRNA levels are not altered by the
absence of Zhx2.
Timp1 mRNA expression in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 or
MO (n=6) (A). Timp1 mRNA expression in female Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 (CCl4
n=5, MO n=4) mice, treated with CCl4 or MO (B). Timp1 mRNA expression in male
BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) or BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) mice,
treated with CCl4 or MO (C). Timp1 mRNA expression in female BALB/cJAfr1/Afr1 or
BALB/cJWT/Afr1 mice (n=6), treated with CCl4 or MO (D). *p<0.05, **p<0.01.
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Figure 3.7 CCl4 administration does not alter hydroxyproline levels in the liver,
regardless of Zhx2 expression.
Hydroxyproline levels (ug) of hydrolyzed tissue homogenate in both Male Zhx2WT/Afr1
and Zhx2Afr1/Afr1 mice treated with CCl4 or MO (n=6) (A). Hydroxyproline levels (ug) of
hydrolyzed tissue homogenate in both Female Zhx2WT/Afr1(CCl4 n=5, MO n=4) and
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Zhx2Afr1/Afr1 (n=6) mice treated with CCl4 or MO (B). Hydroxyproline levels (ug) of
hydrolyzed tissue homogenate in male BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) and
BALB/cJWT/Afr1 (n=6) given CCl4 or MO (C). Hydroxyproline levels (ug) of hydrolyzed
tissue homogenate in female BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) and BALB/cJWT/Afr1
(CCl4 n=6, MO n=5) given CCl4 or MO.
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Figure 3.8 CCl4 administration does not significantly alter TNFα mRNA expression
in the liver, regardless of Zhx2 expression.
TNFα mRNA expression in male Zhx2WT/Afr1(CCl4 n=5, MO n=6) or Zhx2KO/Afr1 (n=6)
mice, treated with CCl4 or MO (A). TNFα mRNA expression in female Zhx2WT/Afr1 (n=6)
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or Zhx2KO/Afr1 (CCl4 n=5, MO n=4) mice, treated with CCl4 or MO (B). TNFα mRNA
expression in male BALB/cJAfr1/Afr1 (n=6) or BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) mice,
treated with CCl4 or MO (C). TNFα mRNA expression in female BALB/cJAfr1/Afr1 (CCl4
n=5, MO n=6) or BALB/cJWT/Afr1 (n=5) mice, treated with CCl4 or MO (D). *p<0.05.
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Figure 3.9 CCl4 administration does alter TGF-β mRNA expression but does not
alter with the absence of Zhx2.
TGF-β mRNA expression in male Zhx2WT/Afr1 (CCl4 n=6, MO n=5) or Zhx2KO/Afr1 (n=6)
mice, treated with CCl4 or MO (A). TGF-β mRNA expression in female Zhx2WT/Afr1
(n=6) or Zhx2KO/Afr1 (CCl4 n=5, MO n=3) mice, treated with CCl4 or MO (B). TGF-β
mRNA expression in male BALBcJAfr1/Afr1 (n=6) or BALBcJWT/Afr1 (CCl4 n=6, MO n=5)
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mice, treated with CCl4 or MO (C). TGF-β mRNA expression in female BALBcJAfr1/Afr1
(CCl4 n=5, MO n=6) or BALBcJWT/Afr1 (n=5) mice, treated with CCl4 or MO (D).
*p<0.05, ****p<0.0001.
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Figure 3.10 CCl4 administration does not alter TGF-β serum levels, regardless of
Zhx2 expression.
TGF-β serum levels in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 (n=6) or
MO (n=4) (A). TGF-β serum levels in female Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated
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with CCl4 (n=6) or MO (n=4) (B). TGF-β serum levels in male BALB/cJAfr1/Afr1 or
BALBcJWT/Afr1 mice, treated with CCl4 (n=6) or MO (n=4) (C). TGF-β serum levels in
female BALBcJAfr1/Afr1 or BALBcJWT/Afr1 mice, treated with mineral oil (n=4, n=3) or
carbon tetrachloride (n=6) (D).
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Figure 3.11 CCl4 administration does alter ALT serum levels but does not worsen
with reduced Zhx2 expression.
ALT serum levels in male Zhx2WT/Afr1 (CCl4 n=6, MO n=5) and Zhx2KO/Afr1 (n=6) mice,
treated with CCl4 or MO for six weeks (A). ALT serum levels in female Zhx2WT/Afr1 (CCl4
n=5, MO n=4) and Zhx2KO/Afr1 (CCl4 n=5, MO n=6) mice, treated with CCl4 or MO for
six weeks (B). ALT serum levels in male BALB/cJWT/Afr1 (n=6) and BALB/cJAfr1/Afr1
(n=6) mice, treated with CCl4 or MO for six weeks (C). ALT serum levels in female
BALB/cJWT/Afr1 (n=6) and BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=4), treated with CCl4 or
MO for six weeks. *p<0.05, *** p<0.001, ****p<0.0001.
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CHAPTER 4. CHARACTERIZATION OF THE ALPHA-FETOPROTEIN
REGULATOR 2 (AFR2) TRAIT IN RESPONSE TO LIVER REGENERATION
4.1 Introduction
The liver has a remarkable ability to repair and regenerate itself in response to
damage. In most liver diseases, regeneration is required after hepatocyte damage,
inflammation, and fibrosis. Subsequent to damage, remaining hepatocytes must be
signaled to proliferate to regain liver mass. This proliferation process is accomplished by
priming the hepatocytes, resulting from increased signaling of c-jun and c-myc and the
production of inflammatory cytokines TNF-α and IL-6 [60, 61]. This signaling cascade
makes it possible for the transition of quiescent hepatocytes to proliferative hepatocytes.
After the initial priming phase, growth factors, including hepatocyte growth factor (HGF)
and endothelial growth factor (EGF), are released [62, 63]. HGF binds to mesenchymalepithelial transition factor (c-Met), activating downstream signaling to induce
proliferation and decrease apoptosis [111]. EGF binds to the EGF receptor (EGFR),
which is also required for activating proliferation [112]. The proliferation phase
continues, in order to replace damaged or apoptotic cells, until the liver regains normal
size; at this point, hepatocytes enter the termination phase. Although there are many
unknowns regarding the termination of hepatocyte regeneration, TGF-β signaling has
been found integral in blocking further hepatocyte proliferation [64]. Through this multiphased process, the liver can orchestrate the regeneration and repair to recover from the
loss of hepatocytes. Understanding regeneration signaling and regulation is beneficial in
developing new treatments for liver disease.
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Experimentally, liver regeneration can be initiated by a variety of methods. In
rodents, two of the most commonly used methods are partial hepatectomy (PH) and
treatment with the hepatotoxin CCl4. PH is conducted by the removal of two-thirds of the
liver lobes. Although these lobes do not grow back, the liver regenerates to make up for
the loss of volume without causing any persistent liver tissue damage [113]. Metabolism
of CCl4 by hepatic Cyp2e1 produces free radicals, which, when administered acutely, can
cause necrosis, apoptosis, and ultimately regeneration of hepatocytes [67].
AFP, which is normally expressed at high levels in the fetal liver and silenced at
birth, is transiently reactivated during liver regeneration. In fact, AFP has become a wellcharacterized marker of liver regeneration. Previous studies found that the C3H/HeJ
mouse strain exhibited greater levels of AFP mRNA after CCl4 treatment than C57BL/6J
mice [82]. The high AFP induction in C3H/HeJ was found to be dominant to the low
induction, and the locus controlling this trait was called alpha-fetoprotein regulator 2
(Afr2); C3H/HeJ and C57BL/6J mice were designated as having Afr2a and Afr2b alleles,
respectively[82]. Further QTL analysis indicated that the gene responsible for the Afr2
trait was located on mouse chromosome 2 [92].
Although previous studies have provided insight regarding the Afr2 trait, the Afr2
gene has not been identified. Previous studies analyzed Afr2 in C3H/HeJ and C57BL/6J
mice but not in other mouse strains. A better understanding of Afr2 in additional mouse
strains could provide insight to identify the Afr2 gene. In particular, we were interested to
know whether the Afr2b allele was unique to C57BL6/J mice or found in other C57BL
substrains. Therefore, in this pilot study, I used CCl4 to induce liver regeneration in mice
of six strains: 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/10SnJ, C57BL/6NJ, and
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C57BL/6J. My results indicated that the Afr2b allele was present in all C57BL substrains,
based on low AFP induction after CCl4 treatment, whereas the other strains contained the
Afr2a allele. Initial studies indicated that the Afr2a allele was dominant over the Afr2b
allele; another study suggested that these two alleles were co-dominant [114]. To further
explore this, we analyzed AFP expression in F1 mice that were generated from a cross
between 129X1/SvJ and C57BL/6J parents. Male and female F1 offspring at eight weeks
of age were injected with CCl4 to induce liver regeneration. I found that F1 mice had
intermediate levels of AFP reactivation compared to 129X1/SvJ and C57BL/6J mice,
consistent with the Afr2a and Afr2b alleles being co-dominant.
An additional regulator of AFP, initially called Afr1, was also found to be the
cause of persistent AFP expression after birth in BALB/cJ mice [82]. In our lab, the Afr1
trait was found to be due to a hypomorphic mutation in the gene Zhx2 [84]. Our lab has
also shown that Zhx2 deficiency can significantly elevate several other genes, including
H19, Gpc3, and LPL [84, 86, 89]. When looking at the Afr2 trait in C3H/HeJ and
C57BL/6J mice, our lab and others have shown that both Zhx2 and Afr2 repress the same
genes but are not genetically linked [82, 86]. We hypothesized that mice with high AFP
reactivation would have elevated levels of Zhx2 targeted genes in this liver regeneration
model. When looking at our data in a pilot study, H19, LPL, and Gpc3 were increased in
mice with high AFP reactivation. Interestingly, even though eight-week-old F1 mice have
an intermediate AFP reactivation, male mice do not have a fold increase in H19 and LPL
while female mice do, suggesting that there might be additional sex-regulated factors
involved in targeting their expression.
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4.2 Results
In an initial pilot study, six-week-old male mice from six different strains were
injected with either MO or CCl4 in a model of liver regeneration. After 72 hours, livers
were collected, and AFP mRNA levels were measured. 129X1/SvJ, C3H/HeJ, and
DBA/2J exhibited significantly increased AFP levels after CCl4 treatment, having a fold
increase of approximately 42, 46, and 42 compared to MO controls, respectively (Fig. 4.1
A-C, Fig. 4.6 A). In contrast, much lower AFP induction was seen in C57BL/6J,
C57BL/6NJ, and C57BL/10SnJ mice, which only had a fold increase of approximately 2,
5, and 3 compared to MO controls, respectively (Fig. 4.1 D-F, Fig. 4.6 A). This result
was confirmed by analyzing serum AFP levels in 129X1/SvJ, C3H/HeJ, and C57BL/6J
mice. Male 129X1/SvJ and C3H/HeJ mice had a 42-fold and 52-fold increase in AFP
serum levels in CCl4-treated mice compared to MO controls, respectively (Fig. 4.2). Male
C57BL/6J mice treated with CCl4 did have an increased serum AFP of 29-fold over MO
treated mice, but the maximum levels remained much lower than the non-C57 lineage
mice (Fig. 4.2).
The long non-coding RNA H19 was originally identified based on a screen for
Zhx2-regulated genes and subsequently found to be regulated by Afr2 [114]. Additional
genes that were identified in our lab to be targets of Zhx2, including Gpc3 and Lpl, also
appeared to be controlled by Afr2 in C57BL/6J and C3H/HeJ mice. To test whether these
three genes also showed the same response to Afr2 in the six strains used in my pilot
study, their expression was analyzed. In 129X1/SvJ, C3H/HeJ, and DBA/2J mice, H19
mRNA expression was increased by 8-, 95-, and 2.3-fold, respectively, compared to MO
controls (Fig. 4.3 A-C, Fig. 4.6 B). H19 levels in C57BL/6J, C57BL/6NJ, and
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C57BL/10SnJ were increased by 1.6-, 1.5- and 0.9-fold, respectively, compared to MO
controls (Fig. 4.3 D-F, Fig. 4.6 B). The same trend was observed for Lpl; levels were
significantly increased in the 129X1/SvJ, C3H/HeJ, and DBA/2J mice roughly 3-fold
after CCl4 treatment (Fig. 4.4 A-C, Fig. 4.6 C). In contrast, Lpl mRNA levels in
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ increased 1.6-, 1.5-, and 0.8-fold, respectively
(Fig. 4.4 D-F, Fig. 4.6 C). Gpc3 mRNA levels increased roughly 7- and 9-fold in
129X1/SvJ and C3H/HeJ mice, respectively, although there was no significant difference
in Gpc3 levels between CCl4- and MO-treat DBA/2J mice (Fig. 4.5 A-C, Fig. 4.6 D).
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ exhibited slightly decreased Gpc3 levels after
CCl4 treatment compared to MO controls (Fig. 4.5 D-F, Fig. 4.6 D).
Cyp2e1 is the major CCl4-metabolizing enzyme in the liver and is responsible for
generating radicals that cause liver damage. A simple explanation for the mouse strain
differences in AFP induction after CCl4 treatment could be differences in Cyp2e1 levels.
We, therefore, analyzed Cyp2e1 levels in all six strains after MO treatment, in which no
liver damage occurred. We found no significant differences in Cyp2e1 mRNA levels
between the six groups in the pilot study (Fig. 4.7 A). Modest differences in Cyp2e1
mRNA levels were found after CCl4 treatment, but these differences did not correlate
with the expression of Afr2 target genes (Fig. 4.7 B). This data suggests that differences
in Cyp2e1 levels cannot account for the Afr2 phenotype.
Previous studies provided conflicting data regarding the dominance of the Afr2
alleles; initial studies indicated that Afr2a was dominant over Afr2b, whereas a second
study indicated that these two alleles were co-dominant [82, 92]. Since 129X1/SvJ mice
showed a robust increase in AFP levels after CCl4 treatment, we used this strain,
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C57BL/6J, and F1 offspring between these two strains to further investigate dominance
of the Afr2 alleles in a full liver regeneration study. Analysis was performed in mice that
were 8 weeks of age since we found that these mice exhibited a more robust AFP
activation than 6-week-old mice used in the pilot study. Seventy-two hours after CCl4 or
MO treatment, male and female mice were killed, and serum and liver tissue were
collected. Liver mRNA analysis showed that AFP mRNA levels in 129X1/SvJ mice had
an 89-fold increase in males and a 68-fold increase in females (Figure 4.7 A, B).
C57BL/6J mice exhibited lower AFP activation in regenerating livers, increasing 11-fold
in males and 5-fold in females (Figure 4-7 C, D). When F1 mice were injected with CCl4,
the activation of AFP was 26-fold in males and 28-fold in females (Figure 4-7 E, F).
Serum AFP levels were also measured in the 8-week-old liver regeneration mice (Figure
4-8 A-B). For both male and female mice, the increase in serum AFP levels was
intermediate between 129X1/SvJ mice (high induction) and C57BL/6J mice (low
induction). Taken together, these data from the full liver regeneration study indicate that
the Afr2a and Afr2b alleles are co-dominant.
As with the six-week-old pilot study mice, the full study male and female
129X1/SvJ, F1, and C57BL/6J were analyzed for gene expression of Zhx2 targets. When
we analyzed H19, we saw a robust increase in 129X1/SvJ mice of 9-fold in males and 8fold in females (Fig. 4.11 A-B, Fig. 4.12 A-B). In C57BL/6J mice, H19 expression was
minimal and increased around 2-fold for males and 3-fold for females in the liver
regeneration model (Fig. 4.11 C-D, Fig. 4.12 A-B). Interestingly, we expected to see
intermediate H19 expression in the F1 mice. However, we saw a pattern that differed
between male and female mice. Male F1 mice had a minimal increase of 2-fold in H19
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expression, similar to C57BL/6J mice (Fig. 4.11 E, Fig. 4.12 A). Females had a robust
increase in H19 mRNA expression of 29-fold, which was even greater than the increase
we saw in 129X1/SvJ mice. (Fig. 4.11 F, Fig. 4.12 B). When we look at LPL mRNA
expression, we see a similar pattern. 129X1/SvJ mice had a robust increase of around 10fold in males and 7-fold in females mice during liver regeneration (Fig. 4.13 A-B, Fig
4.14 A-B). C57BL/6J mice also had a minimal increase in LPL mRNA levels of 3-fold in
males and remained the same in females (Fig. 4.13 C-D, Fig. 4.14 A-B). In F1 male mice,
we see LPL expression that minimally increases by 3-fold, like C57BL/6J mice (Fig. 4.13
E, Fig. 4.14 A). F1 females had a more robust increase of LPL of 9-fold, which was more
similar to the 129X1/SvJ mice (Fig. 4.13 F, Fig 4.14 B). When looking at Gpc3 mRNA
expression, we saw expression changes that matched the pattern of AFP expression.
129X1/SvJ male and female mice had a Gpc3 mRNA expression increase of around 10.6
and 8-fold (Fig. 4.15 A-B, Fig. 4.16 A-B). C57BL/6J male and female mice had a much
lower increase of Gpc3 expression that was 4.6- and 1.43-fold greater (Fig. 4.15 C-D,
Fig. 4.16 A-B). F1 male and female mice had fold increases and expression of Gpc3 that
were more intermediate at 7.4- and 3-fold (Fig. 4.15 E-F, Fig. 4.16 A-B).
An transient increased liver weight:body weight ratio is observed in the CCl4 in a
model of liver regeneration [115]. The full liver regeneration study was analyzed for liver
weight:body weight ratio to determine if different strains of mice responded to CCl4
treatment. Both male and female mice in all three strains had similar liver weight: body
weight ratio increases when undergoing CCl4 treatment (Figure 4.17 A-F).
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4.3 Discussion
Results in this chapter provide new insight regarding the Afr2 phenotype. My data
from the pilot study showed that male mice from 129X1/SvJ, C3H/HeJ, and DBA/2J
strains displayed robust AFP activation in a regeneration model, while the mice from the
C57BL lineage (C57BL/6J, C57BL/6NJ, and C57BL/10SnJ) show minimal AFP
reactivation. When doing a full study using an 8-week-old mouse model of liver
regeneration with 129X1/SvJ and C57BL/6J mice, we were able to see that 129X1/SvJ
mice displayed robust AFP activation. In contrast, C57BL/6J mice displayed much lower
AFP levels after CCl4 injection. When F1 mice, a cross of both pairings, were injected,
they displayed an intermediate activation of AFP.
From the 6-week-old initial pilot study, we determined that mice from the C57BL
lineage (C57BL/6J, C57BL/6NJ, and C57BL/10SnJ) have the Afr2b phenotype, while
other strains across several other lineages (129X1/SvJ, C3H/HeJ, and DBA/2J) have the
Afr2a phenotype. This finding confirms previous literature showing that C3H/HeJ mice
have significantly higher AFP reactivation over the C57BL/6J mice [82]. Our data from
the pilot study additionally shows that other strains outside of C3H/HeJ mice also display
the Afr2a trait, while other mice in the C57BL lineage continue to display the Afr2b.
Serum AFP levels also confirmed that mice with the Afr2a trait have significantly higher
reactivation in liver regeneration than mice from the C57BL lineage. This data supports
that both 129X1/SvJ and C57BL/6J mice served as a suitable choice for both the Afr2a
and Afr2b for a full 8-week-old mouse liver regeneration study, respectively.
It is known that Zhx2 (Afr1) and Afr2 are not genetically linked both regulate
AFP independently of each other along with other essential liver genes [82, 86]. Our pilot
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study data confirmed that C3H/HeJ and 129X1/SvJ mice both have increases H19, LPL,
and Gpc3 levels, but DBA/2J mice only have an increase in LPL. This might suggest that
the gene responsible for Afr2 might not be sufficient to alter these gene’s expression
alone in these strains of mice and also might rely on other gene changes.
With the full liver regeneration study, we were able to determine that F1 mice
have intermediate AFP activation, suggesting that the two Afr2 alleles are co-dominant.
The AFP mRNA ΔΔCT average for 129X1/SvJ mice was 3.38, whereas C57BL/6J mice
were 0.22. The F1 mice have an average of 1.23, falling in between those two strains.
This data supports a previous finding that F1 offspring from C3H/HeJ and C57BL/6J
mice have an intermediate AFP response in a model of liver regeneration [114]. Our data
additionally shows that using other strains that have the Afr2a trait for the F1 breeding
also results in intermediate AFP reactivation.
The data from the pilot study suggests that the Afr2b trait is unique to the mice
from the C57BL lineage. Identifying the point in the evolution of different inbred mouse
strains when the Afr2b allele first appeared could help identify the causal Afr2 gene.
Future experiments could focus on repeating the liver regeneration model with mouse
strains closer to the branching that led to the C57 lineage, including YBR/EiJ and C58/J
mice, to determine if this trait is present in these mice. Combined knowledge gained from
this experiment and available sequencing might determine potential genes that could
result in AFP regulation.
The full liver regeneration data suggests that the Afr2a and Afr2b alleles are codominant. F1 offspring from 129X1/SvJ and C57BL/6J parental mice have an
intermediate expression of AFP mRNA and serum levels. Using what we know from
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these data, we potentially can breed F1 mice to map and identify the gene responsible for
Afr2. Previous studies bred C3H/HeJ and C57BL/6J mice mapped the potential Afr2
gene to a region on chromosome 2, but the gene responsible was never identified [92].
Using 129X1/SvJ and C57BL/6J mice, the offspring of two F1 mice should display AFP
reactivation at high, intermediate, and low levels at a frequency of 25%:50%:25% [114].
Like the previous study, we could identify these high, intermediate, and low AFP
activators with serum AFP and perform QTL analysis to determine a region of interest in
the Afr2 trait.
Our pilot mouse data looking at H19 and LPL, and Gpc3 suggest that Afr2 does
increase Zhx2 targets. Although DBA/2J mice do not have an increase in H19 and Gpc3,
which might suggest additional genes that might be involved in targeting these gene’s
expression. The data from our full mouse study suggest that 129X1/SvJ with the Afr2a
allele have robust increases in H19, LPL, and Gpc3 levels, while C57BL/6J mice with the
Afr2b allele have lower fold increases of these genes. F1 male and female mice with both
alleles have intermediate levels of Gpc3. Interestingly, F1 male mice have minimal
increases in H19 and LPL levels, where females have more significant increases. Our
data could suggest that there could be additional sex-dependent factors that might affect
H19 and LPL levels.
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Figure 4.1 AFP activation during regeneration is reduced in the mice from the C57
lineage compared to other mouse strains.
AFP mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO or
CCl4 injection (n=4) (A). AFP mRNA expression in six-week-old male C3H/HeJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (B). AFP mRNA expression in sixweek-old male DBA/2J mice with one MO (n=3) or CCl4 injection (n=5) (C). AFP
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or
CCl4 injection (n=6) (D). AFP mRNA expression in six-week-old male C57BL/6NJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (E). AFP mRNA expression in sixweek-old male C57BL/10SnJ mice treated with one MO (n=3) or CCl4 injection (n=6)
(F). *p<0.05, **p<0.01, ****p<0.0001.
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Figure 4.2 Afr2a trait in non-C57 strains of mice significantly increases serum AFP
levels compared to C57BL/6J mice.
AFP serum levels male six-week-old 129X1/SvJ, C3H/HeJ, and C57BL/6J (n=4,
C57BL/6J-MO n=3) were treated acutely with either MO or CCl4 in a model of liver
regeneration. **p<0.01, ****p<0.0001.
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Figure 4.3 Afr2a trait increases H19, a target gene of Zhx2, in a model of liver
regeneration.
H19 mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO (n=4)
or CCl4 injection (n=5) (A). H19 mRNA expression in six-week-old male C3H/HeJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (B). H19 mRNA expression in sixweek-old male DBA/2J mice treated with one MO (n=4) or CCl4 injection (n=6) (C). H19
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or
CCl4 injection (n=5) (D). H19 mRNA expression in six-week-old male C57BL/6NJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (E). H19 mRNA expression in six75

week-old male C57BL/10SnJ mice treated with one MO (n=4) or CCl4 injection (n=6)
(F). *p<0.05, **p<0.01.
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Figure 4.4 Afr2a trait increases LPL, a target gene of Zhx2, in a model of liver
regeneration.
LPL mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO (n=4)
or CCl4 injection (n=5) (A). LPL mRNA expression in six-week-old male C3H/HeJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (B). LPL mRNA expression in sixweek-old male DBA/2J mice treated with one MO (n=4) or CCl4 injection (n=6) (C). LPL
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or
CCl4 injection (n=6) (D). LPL mRNA expression in six-week-old male C57BL/6NJ mice
treated with one MO (n=4) or CCl4 injection (n=6) (E). LPL mRNA expression in sixweek-old male C57BL/10SnJ mice treated with one MO (n=4) or CCl4 injection (n=6)
(F). *p<0.05, **p<0.01.
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Figure 4.5 Afr2a trait increases Gpc3, a target gene of Zhx2, in a model of liver
regeneration.
Gpc3 mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO
(n=4) or CCl4 injection (n=5) (A). Gpc3 mRNA expression in six-week-old male
C3H/HeJ mice treated with one MO (n=4) or CCl4 injection (n=6) (B). Gpc3 mRNA
expression in six-week-old male DBA/2J mice treated with one MO (n=4) or CCl4
injection (n=5) (C). Gpc3 mRNA expression in six-week-old male C57BL/6J mice
treated with one MO (n=4) or CCl4 injection (n=6) (D). Gpc3 mRNA expression in sixweek-old male C57BL/6NJ mice treated with one MO (n=3) or CCl4 injection (n=6) (E).
Gpc3 mRNA expression in six-week-old male C57BL/10SnJ mice treated with one MO
(n=4) or CCl4 injection (n=6) (F). *p<0.05, **p<0.01.
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Figure 4.6 Afr2a trait increases AFP and target genes of Zhx2 in a model of liver
regeneration.
AFP mRNA expression fold change in six-week-old male 129X1/SvJ, C3H/HeJ, DBA/2J,
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated with one MO or CCl4 injection
(A). H19 mRNA expression fold change in six-week-old male 129X1/SvJ, C3H/HeJ,
DBA/2J, C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated with one MO or CCl4
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injection (B). LPL mRNA expression fold change in six-week-old male 129X1/SvJ,
C3H/HeJ, DBA/2J, C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated with one
MO or CCl4 injection (C). Gpc3 mRNA expression fold change in six-week-old male
129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated
with one MO or CCl4 injection (D).
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Figure 4.7 AFP reactivation through Afr2 is not dependent on Cyp2E1.
Cyp2E1 mRNA expression of six-week-old male 129X1/SvJ, C3H/HeJ, DBA/2J,
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ treated with MO (n=4, C57BL/6NJ n=3) (A).
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Cyp2E1 mRNA expression of male 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J,
C57BL/6NJ, and C57BL/10SnJ treated with CCl4 (n=6, 129X1/SvJ, C3H/HeJ,
C57BL/6NJ n=5). *p<0.05, **p<0.01.
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Figure 4.8 F1 mice display an intermediate activation of AFP in liver regeneration.
AFP mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5)
or CCl4 (n=7) (A). AFP mRNA expression in eight-week-old female 129X1/SvJ mice
injected with MO (n=6) or CCl4 (n=6) (B). AFP mRNA expression in eight-week-old
male C57BL/6J mice injected with MO (n=5) or CCl4 (n=6) (C). AFP mRNA expression
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in female eight-week-old C57BL/6J mice injected with MO (n=6) or CCl4 (n=9)(D). AFP
mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4
(n=7)(E). AFP mRNA expression in female F1 mice injected with MO (n=7) or CCl4
(n=8) (F). *p<0.05, **p<0.01, ***p<0.001.
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Figure 4.9 F1 mice display an intermediate activation AFP in a model of liver
regeneration.
AFP mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice
injected with MO or CCl4 (A). AFP mRNA fold change in eight-week-old female
129X1/SvJ, F1, and C57BL/6J mice injected with MO or CCl4 (B).
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Figure 4.10 F1 mice display intermediate AFP serum reactivation levels in a model
of liver regeneration.
AFP serum levels of eight-week-old male 129X1/SvJ, C57BL/6J, and F1 mice were
assayed after acute treatment with mineral oil (n=5) or CCl4 (n=7, C57BL/6J CCl4 n=6)
(A). AFP serum levels of eight-week-old female 129X1/SvJ, C57BL/6J, and F1 mice
measured after acute treatment with mineral oil (129X1/SvJ n=6, C57BL/6J n=4, F1 n=7)
or CCl4 (129X1/SvJ n=6, C57BL/6J n=9, F1 n=8). *p<0.05, ****p<0.0001.
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Figure 4.11 F1 mice display an intermediate activation H19, a target of Zhx2.
H19 mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5)
or CCl4 (n=6) (A). H19 mRNA expression in eight-week-old female 129X1/SvJ mice
injected with MO (n=5) or CCl4 (n=6) (B). H19 mRNA expression in eight-week-old
male C57BL/6J mice injected with MO (n=6) or CCl4 (n=7) (C). H19 mRNA expression
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in eight-week-old female C57BL/6J mice injected with MO (n=5) or CCl4 (n=8) (D).
H19 mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4
(n=7) (E). H19 mRNA expression in eight-week-old female F1 mice injected with MO
(n=7) or CCl4 (n=9) (F). *p<0.05, **p<0.01, ***p<0.001.
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Figure 4.12 F1 female mice display an increase in H19 expression in a model of liver
regeneration.
H19 mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice
injected with MO or CCl4 (A). H19 mRNA fold change in eight-week-old female
129X1/SvJ, F1, and C57BL/6J mice injected with MO or CCl4 (B).
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Figure 4.13 F1 mice display an intermediate activation of LPL, a target of Zhx2.
LPL mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5)
or CCl4 (n=6) (A). LPL mRNA expression in eight-week-old female 129X1/SvJ mice
injected with MO (n=5) or CCl4 (n=7) (B).LPL mRNA expression in eight-week-old
male C57BL/6J mice injected with MO (n=5) or CCl4 (n=7) (C). LPL mRNA expression
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in eight-week-old female C57BL/6J mice injected with MO (n=6) or CCl4 (n=9) (D). LPL
mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4 (n=7)
(E). LPL mRNA expression in female F1 mice injected with MO or CCl4 after injection
at 8-weeks of age (n=6, n=9)(F). **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 4.14 F1 female mice have an increase in LPL expression in a model of liver
regeneration.
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LPL mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice
injected with MO or CCl4 (A). LPL mRNA fold change in eight-week-old female
129X1/SvJ, F1, and C57BL/6J mice injected with MO or CCl4 (B).
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Figure 4.15 F1 mice display an intermediate activation of Gpc3, a target of Zhx2.
Gpc3 mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=3)
or CCl4 (n=5) (A). Gpc3 mRNA expression in eight-week-old female 129X1/SvJ mice
injected with MO (n=3) or CCl4 (n=4) (B). Gpc3 mRNA expression in eight-week-old
male C57BL/6J mice injected with MO (n=3) or CCl4 (n=5) (C). Gpc3 mRNA expression
in eight-week-old female C57BL/6J mice injected with MO (n=3) or CCl4 (n=4) (D).
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Gpc3 mRNA expression in eight-week-old male F1 mice injected with MO (n=3) or CCl4
(n=6) (E). Gpc3 mRNA expression in female F1 mice injected with MO (n=3) or CCl4
(n=5) after injection at 8-weeks of age (F). *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 4.16 F1 mice display an intermediate increase in Gpc3 expression in a model
of liver regeneration.
Gpc3 mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice
injected with MO or CCl4 (A). Gpc3 mRNA fold change in eight-week-old female
129X1/SvJ, F1, and C57BL/6J mice injected with MO or CCl4 (B).
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Figure 4.17 129X1/SvJ, C57BL/6J, and F1 mice respond to liver regeneration with
CCl4.
Liver weight/body weight ratio in eight-week-old male 129X1/SvJ mice injected with
MO (n=5) or CCl4 (n=7) (A). Liver weight/body weight ratio in eight-week-old female
129X1/SvJ mice injected with MO (n=6) or CCl4 (n=7) (B). Liver weight/body weight
ratio in eight-week-old male C57BL/6J mice injected with MO (n=6) or CCl4 (n=7) (C).
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Liver weight/body weight ratio in eight-week-old female C57BL/6J mice injected with
MO (n=6) or CCl4 (n=9) (D). Liver weight/body weight ratio in eight-week-old male F1
mice injected with MO (n=4) or CCl4 (n=7) (E). Liver weight/body weight ratio in female
F1 mice injected with MO (n=7) or CCl4 (n=9) after injection at 8-weeks of age (F).
**p<0.01, ***p<0.001, ****p<0.0001.
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS
Inbred mice have been kept as pets and bred for their interesting phenotypes,
including coat color, for thousands of years [70]. However, since their use in biomedical
research, many genetic differences between different inbred strains have been observed.
For example, well documented differences have been found between the frequently used
substrains C57BL/6J and C57BL/6N mice. Research has shown many genetic and
phenotypic differences between these two substrains, including differences in glucose
tolerance and insulin secretion, making them suited for different experimentation models
[72, 73]. Outside these substrains, many additional unique phenotypes have been
discovered. Identifying and using genetic and phenotypic differences across strains and
substrains of mice can be a helpful tool to gain insight into signaling pathways and
disease.
The data reported in this dissertation focuses on showing how two genes involved
in AFP regulation, Zhx2 (Afr1) and Afr2, can impact liver physiology over the mouse
species. Chapter 3 focuses on determining if the hypomorphic mutation of Zhx2 in
BALB/cJ mice is responsible for the Hfib1 liver fibrosis phenotype. Previous research
identified a region on chromosome 15 in BALB/cJ mice leading to increased liver
fibrosis, overlapping with Zhx2 [84, 90]. Based on my results, I eliminated Zhx2 as the
causal gene involved in increased fibrosis in BALB/cJ mice. Mice having diminished
Zhx2 levels did not differ in fibrosis, inflammation, or damage markers. Chapter 4
focuses on identifying if AFP reactivation during liver regeneration due to the Afr2 trait
is dominant and present across different mouse strains. Previous work identified that AFP
levels are significantly higher in response to liver regeneration in C3H/HeJ mice than
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C57BL/6J [82]. It was determined that this was due to the monogenic Afr2 trait, which
had two different alleles, Afr2a and Afr2b, leading to high and low levels of AFP,
respectively [92]. My data shows that the allele responsible for diminished AFP mRNA
and serum reactivation in a 6-week-old liver regeneration model, Afr2b, was expressed in
mice across three strains in the C57BL lineage. The Afr2a allele leads to significant AFP
mRNA and serum level increases in 129X1/SvJ, C3H/HeJ, and DBA/2J mice. This data
suggests that the gene responsible for Afr2 might be mutated within the C57BL lineage,
leading to low AFP reactivation in response to CCl4 treatment . This finding was further
validated by conducting an 8-week- old liver regeneration model in 129X1/SvJ,
C57BL/6J, and F1 mice that were a cross of these two strains. As expected, 129X1/SvJ
mice had robust AFP reactivation while C57BL/6J mice did not. Interestingly, the F1
mice displayed an intermediate level of AFP reactivation, suggesting that the both Afr2a
and Afr2b alleles are co-dominant. Overall, this data suggests that both regulators of AFP
have an impact on liver functioning and pathophysiology.
5.1 Hfib1
The data collected during the Hfib1 study suggests that the Zhx2 mutation found
in BALB/cJ mice is not responsible for the increased fibrosis phenotype seen in this
strain. Although, the severity of disease in the treated groups was highly variable, which
could lead to a masking of the effect. It is possible that the variation we see is due to
samples being taken from different lobes of the liver. In a paper from 1997, expression of
fibrinogen genes were found to be different in each lobe [116]. In other CCl4 studies,
inbred rat models were found to have a high level of variation between individuals [117,
118]. A study reported that gene expression differences in pathways involved in
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immunity, steroid metabolism, and lipid metabolism could lead to variation between mice
in CCl4 treatment models [119]. In my study, I found that many mRNA fibrosis markers
were varied; for example, male Zhx2KO/Afr1 treated with CCl4 had an ACTA2 mRNA
expression average of 2.05 with a standard deviation of 1.72. With such a high standard
deviation, the data is unreliable, and other analysis should be done. If there was a minor
effect, the variation of this data could potentially conceal it. Several other methods for
administration of CCl4 induce liver damage, including oral gavage, subcutaneous
injection, and inhalation [120-122]. Unfortunately, it seems that these methods of
administration also see variation and have more significant mortality. Treating mice with
a lower amount of CCl4 might allow us to determine differences between the treatment
groups. If there was some protection in mice with wild-type Zhx2, it might be
overwhelmed by high prolonged CCl4 doses. Smaller studies looking at lower CCl4
dosing could be potentially done in these mice to determine if there is a small effect. It is
also possible that the number of mice (n) used in CCl4- treated groups was too small.
Some studies have n values up to 10 to minimize variability [123]. Another option for
reducing variability would be to change the liver fibrosis model entirely. Bile duct
ligation (BDL) is another model for promoting liver fibrosis that is commonly used. In a
study looking at various models for liver fibrosis induction, BDL is a consistent way of
inducing fibrosis and liver failure within two months of surgery [124]. Although more
invasive, this might be a better model for observing any effect that Zhx2 might have on
the fibrosis seen in mice.
With such high mRNA variability of fibrosis markers, additional protein analysis
should be performed. Dr. Shirley Qiu analyzed levels of αSMA in the livers of these mice
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but found that there were no significant differences between CCl4-treated mice (data not
shown). Protein levels of collagen 1a1 and Timp1 could also be analyzed to determine
any differences in fibrosis markers.
In addition to Zhx2, many genes fall within the Hfib1 region on Chromosome 15.
Potentially, one of these genes may be responsible for the increased fibrosis phenotype
previously seen in BALB/cJ mice. As previously discussed, several genes within this
region can play a role in liver fibrosis, including Col14a1 and Has2. Col14a1 (Undulin) is
increased during liver fibrosis, found in areas of concentrated fibrosis [125]. In addition,
Hyaluronan Synthase 2 (Has2) has been frequently observed in liver disease, with it
being produced by the hepatic stellate cells during fibrosis. Further studies looking into
the candidate genes in the region might determine which is responsible for the Hfib1
phenotype.
5.2 Afr2
My results from the Afr2 study show that C57BL lineage mice have display low
AFP reactivation in response to CCl4. In contrast, the other strains used in the study have
a robust increase of AFP during liver regeneration. This finding confirms previous
studies but further shows AFP reactivation differences across several strains [82, 92].
Although it is known that this Afr2 trait is involved in liver regeneration, the mechanism
involved remains unknown. Liver regeneration is a process that happens over a few days
and activates many pathways required for proliferation and inflammation [126]. We
could further investigate the Afr2 trait and its mechanism of action by looking at
129X1/SvJ and C57BL/6J mice throughout liver regeneration. Mice could have blood
collected before the initial injection and one, three, five, and seven days post-injection to
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monitor AFP levels in the serum. mRNA expression of markers involved in the initial
priming process of liver regeneration, including TNF-α and IL-6, can be assessed in the
livers of these mice soon after injection [127]. Factors associated with hepatocyte
proliferation, including HGF and EGF, could also be assessed throughout liver
regeneration [62]. Measuring early differences in liver damage markers, such as ALT,
might also be informative in how much damage is occurring in these mice in the first
several days of liver regeneration.
In my Afr2 study looking at F1 mice, I was able to show these mice had an intermediate
level of reactivation of AFP during liver regeneration. This data would suggest that Afr2a
and Afr2b are co-dominant. Although it was previously thought that Afr2a was dominant,
my data supports more recent findings that Afr2a/b mice have an intermediate phenotype
[82, 92]. We could further use this information to map and determine the gene
responsible for Afr2. Two F1 mice can be bred to obtain offspring that are Afr2a/a,
Afr2b/b, and Afr2a/b. These high, low, and intermediate mice can be used to map the
possible position of the gene responsible for Afr2. Previous studies looking at Afr2 using
C3H/HeJ and C57BL/6J mice mapped the potential gene responsible for AFP
reactivation in this model to a region on Chromosome 2 [92]. However, the causal gene
was never identified. Using both the 129X1/SvJ mice and a less invasive way to screen
large amounts of offspring through serum AFP, we should be able to remap the Afr2
region.
My data also found that there might be additional factors involved in the extent to
whicgh Afr2 alters expression of genes that are also targets of Zhx2. H19 expression fold
change was not as robust in 129X1/SvJ and DBA/2J mice compared to C3H/HeJ mice,
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while their AFP reactivation was similar. This finding would suggest that regulation of
H19 might require regulation besides Afr2. When looking at the 8-week-old study, H19
and Lpl were not significantly different in the F1 male mice but were in females. This
result might also suggest that a sex-dependent mechanism regulates these target genes. In
previous studies, H19 was found to be female-biased in the mouse eye [128]. It has also
been seen that increases in steroid hormones, like estrogen, cause increase H19
expression within the tissues and were diminished in ovariectomized mice [129]. Thus,
H19 activation in the liver in response to injury might result from an estrogen-regulated
mechanism in this model of liver regeneration. Studies could be done to look at estrogen
levels before, during, and after liver regeneration to test if increases in estrogen might
play a role in increasing H19 and Lpl levels in female mice.
5.3 Summary
Both Zhx2 (Afr1) and Afr2 have been found to play a role within different mouse
strains in regulating AFP expression in development and during liver injury. Zhx2 seems
to affect the whole range of liver disease, including diet-induced fatty liver and
hepatocellular carcinoma [89, 130]. Although my studies suggest Zhx2 is not involved in
the extent of liver fibrosis, many other genes within the region might be responsible for
Hfib1. AFP reactivation during liver injury is caused by the Afr2 trait [82, 92]. Although
the gene has not been identified, my findings confirmed that the C57BL lineage has
lower AFP activation levels than other strains and that this trait is co-dominant [92]. In
future studies, identifying the gene responsible for the Afr2 could be of benefit. As with
the case of Zhx2, the gene responsible for Afr2 could play a potential role in human liver
disease. In addition, understanding more about the possible mechanisms involved in
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Zhx2 and Afr2’s regulation of liver function might help develop new targets in treating
liver disease.
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